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Abstract
Aims: Three types of cardiovascular calcification are commonly found in humans: arterial
calcification, intimal calcification, and calcific aortic valve disease. Very little is known about
the mechanisms driving cardiovascular calcification despite serious clinical implications and
a clear association with morbidity and mortality. Indeed, it is even unclear whether the same
factors are involved in arterial, intimal, and valvular calcification. The objective of this study
was to elucidate the effects of an angiotensin II type 1 receptor blocker (ARB) on the
progression of cardiovascular calcification in male New Zealand White rabbits. Where
appropriate, statins were examined in conjunction and in combination with ARBs.
Methods and Results: In vivo and ex vivo techniques were used to assess overall disease
burden and the extent of calcification including magnetic resonance imaging, microcomputed tomography, histology, and immunohistochemistry. ARB administration
significantly inhibited progression of arterial calcification (2.80 ± 1.17 versus 0.01 ± 0.01 %
calcified tissue in Cholesterol and ARB-treated, respectively; P < 0.05), but not intimal or
valvular calcification. ARB treatment significantly reduced atherosclerotic lesion area when
delivered alone (95.50 ± 1.94 versus 61.61 ± 10.17 % lesion area in Cholesterol and ARBtreated, respectively; P < 0.05), but not when combined with statin therapy (92.39 ± 3.25 %
in ARB+Statin; P < 0.05 when compared to ARB monotherapy). Finally, ARB-treated
animals had significantly increased valvular calcium.
Conclusions: This study provides evidence that ARBs robustly inhibit arterial calcification
and is the first to suggest ARBs as a novel treatment option for those at risk for
cardiovascular calcification. It also suggests that ARBs may not be beneficial for those at risk
for intimal or valvular calcification. These disparate results suggest that the three types of
cardiovascular calcification are distinct from one another and provides impetus to further
examine the underlying molecular mechanisms at play in these debilitating disease processes.
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Chapter 1

1

General Introduction

Cardiovascular calcification can be broadly grouped into three categories: arterial
calcification, intimal calcification, and calcific aortic valve disease (Figure 1.1). Each
class of cardiovascular calcification is associated with unique pathologies. While arterial
calcification is mainly associated with diabetes mellitus (DM) and chronic kidney disease
(CKD),1 intimal calcification and calcific aortic valve disease is found more commonly in
the elderly and associated with typical risk factors of atherosclerosis.2-5
Clinical consequences of cardiovascular calcification are numerous and diverse. In
dialysis patients, arterial calcification is responsible for calcific uremic arteriolopathy, a
condition causing necrosis of the skin which has a very high mortality rate.6 Moreover,
arterial calcification is correlated with future cardiovascular events in patients with DM
and is a strong predictor of mortality in patients with CKD.7,8 Intimal calcification is
associated with an increased risk of myocardial infarction (MI)9,10 and may promote
plaque instability.11,12 Patients who have aortic valve disease without concomitant
coronary artery disease have a 50% increased risk of MI and cardiovascular death
compared to patients who have a normal aortic valve,13-16 and calcification of valvular
tissue is recognized as the primary mode of valve failure in both native and bio-prosthetic
valves.17
Despite the myriad of clinical implications and the clear association with morbidity and
mortality, very little is known about the underlying molecular mechanisms leading to
cardiovascular calcification. Indeed, it is even unclear whether the same mechanisms are
at play in arterial, intimal, and valvular calcification. Most importantly, there is no
preventive therapy available to physicians or patients.

1.1 Renin-Angiotensin System
Dysregulation of the Renin-Angiotensin System (RAS) is well known to promote
hypertension and cardiovascular disease.18-20 The RAS is normally responsible for
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Figure 1.1: The sinus of valsalva and three types of cardiovascular calcification.
Arterial calcification presents as large masses localized along the internal elastic lamina
and within the tunica media. Intimal calcification typically begins as micro-calcifications
within the cholesterol-rich atherosclerotic plaque, which develops in the cellular tunica
intima. Calcific aortic valve disease also involves micro-calcifications, typically near the
base of the collagenous fibrosa layer of the aortic valve.
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maintaining fluid volume and preventing ischemia during fluid loss. The main vasoactive
agent, angiotensin II (AngII), induces vasoconstriction and sympathetic activation, raises
aldosterone levels, and promotes salt and water retention via the AngII type 1 receptor
(AT1R).21 The canonical RAS cascade is rather simple (Figure 1.2). Angiotensinogen, the
precursor peptide that is produced in the liver, is cleaved by renin, an enzyme produced
by juxtaglomerular cells in the kidney in response to low blood pressure or low sodium
levels.22 Cleavage of angiotensinogen by renin produces angiotensin I (AngI), which
appears to have no biological activity.23 AngI is further cleaved by angiotensin converting
enzyme (ACE), usually in the endothelium,24 to produce AngII.21 However, ACE is not
the only AngII-producing enzyme in the cardiovascular system. Several groups have
shown that mast cell-derived chymase and cathepsin G can also produce AngII in blood
vessels,25 the heart,26,27 and heart valves.28-30 Angiotensin(1–12), which contains two
extra amino acids on the C-terminus of AngI, is the substrate for chymase production of
AngII.31-33 Regardless of its source, AngII exerts its cellular effects via the ATIR. Certain
cell types, including much of the cardiovascular system, also express the AngII type 2
receptor which, when bound by AngII, generally opposes the effects of the AT1R.34
There are a number of clinically available pharmaceuticals that modulate the RAS
(Figure 1.2). The direct renin inhibitor aliskiren first became available in 2007 and
inhibits the rate limiting step of the RAS cascade, the conversion of angiotensinogen to
AngI, thereby reducing the synthesis of all downstream components.21 ACE inhibitors
(ACEIs), as their name implies, directly inhibit ACE and prevent the conversion of AngI
into AngII.24 They also prevent ACE-mediated degradation of bradykinin which elicits
positive cardiovascular effects.24 Unfortunately, chronic administration of ACEIs
sometimes leads to reactivation of AngII, which is linked to poorer outcomes.35 Finally,
AngII type 1 receptor blockers (ARBs) inhibit the binding of AngII to the AT1R and thus
they are able to inhibit the function of AngII regardless its source, which is particularly
important given the capability of mast cell-derived chymase to produce AngII.
Furthermore, the affinity of ARBs for the AT1R provide an opportunity for AngII to bind
the AngII type 2 receptor and elicit positive cardiovascular effects. Finally, ARBs are
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Figure 1.2: The canonical pathway of the renin-angiotensin system (RAS).
Angiotensinogen, produced in the liver, is cleaved by renin, an enzyme produced by
juxtaglomerular cells in the kidney, to form angiotensin I (AngI). Angiotensin converting
enzyme (ACE), typically found in the endothelium, cleaves AngI to form angiotensin II
(AngII). AngII acts through the AngII type 1 receptor (AT1R) to elicit vasoconstriction,
sympathetic activation, salt retention, and water retention. Pharmaceutical inhibitors of
the RAS (shown in red) include direct renin inhibitors (DRIs), ACE inhibitors (ACEIs),
and angiotensin receptor blockers (ARBs).
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generally more tolerable than other antihypertensives, with significantly less cough and
angioedema.18,36,37

1.2 Arterial Calcification
Arterial calcification, also known as medial artery calcification or Mönckeberg sclerosis,
38

involves calcification of the internal elastic lamina and elastic fibers within the medial

layer of the artery resulting in hardening and increased pulse pressure (Figure 1.1).
Commonly associated with advanced age, hypertension, CKD, DM, and osteoporosis,
arterial calcification is closely related to cardiovascular morbidity and mortality.8,39,40

1.2.1 Initiation and Progression of Arterial Calcification
Originally considered a passive, degenerative and, most importantly, irreversible process,
arterial calcification is now considered to be a highly regulated process resembling
natural bone formation (Figure 1.3).41,42 The initiating event appears to be the deposition
of hydroxyapatite-like material on degraded or damaged elastin fibers. Vascular smooth
muscle cells (VSMCs) cultured in a pre-calcified elastin matrix down-regulated their
typical biological markers (α-smooth muscle actin and myosin heavy chain) and upregulated markers of osteogenic differentiation including core-binding factor alpha1/runtrelated transcription factor 2 (Cbfα1/Runx2), alkaline phosphatase, and osteocalcin
(OCN).43 When the calcified conditions were removed, VSMCs reverted to their original
phenotype, which suggests some potential for regression. In response to elevated levels of
extracellular phosphate, VSMCs release matrix vesicles that contain calcium and
phosphate ions, especially if local (matrix gla-protein) or circulating (feutin-A) inhibitors
are lost.44 It is likely, therefore, that VSMCs transdifferentiate to an osteoblast-like
phenotype after the local microenvironment is altered.

1.2.2 Osteoblast Transdifferentiation of VSMCs
An elegant fate-mapping study by Speer et al.45 has shown VSMCs are capable of
osteoblast transdifferentiation in calcifying arteries. This transdifferentiation was
associated with downregulation of smooth muscle cell (SMC) markers and upregulation
of the osteoblast transcription factor Cbfα1/Runx2.46 Additional osteoblast transcription
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Figure 1.3: The cellular interactions underlying cardiovascular calcification. Arterial
calcification (top right) involves calcification of the internal elastic lamina and tunica
media, a cellular environment consisting of vascular smooth muscle cells (VSMCs).
Intimal calcification (top centre) occurs within the cholesterol-rich atherosclerotic plaque,
and environment rich with VSMCs, macrophages, lymphocytes, and mast cells. Calcific
aortic valve disease (bottom left) exists primarily in the collagenous fibrosa of the aortic
valve, involving native valvular interstitial cells (VICs) as well as macrophages,
lymphocytes, and mast cells. Solid arrows represent known interactions; dashed arrows
represent unclear or unknown processes.
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factors, including muscle segment homeobox 2 (Msx2) and osterix, have also been
implicated in VSMC transdifferentiation and in the progression of arterial calcification.
47,48 A number

of factors have been shown to induce VSMC differentiation and promote

an osteoblast-like phenotype including fibroblast growth factor-2,49 tumor necrosis
factor-alpha,50 oxidized-low density lipoprotein (LDL),47 and bone morphogenetic
protein (BMP) 2.51 Although tremendous progress has been made in this area, the
molecular mechanisms underlying this process remain to be fully defined.

1.2.3 RAS and Osteoblast Transdifferentiation
There is growing evidence that vasoactive agents are important modulators of vascular
calcification. Naturally existing peptides such as endothelin-1 and urotensin II can
promote arterial calcification, while others – adrenomedullin and C-type natriuretic
peptide – act to inhibit its progression.52-54 Until recently, the role of the RAS and its
vasoactive agent, AngII, had not been thoroughly investigated. AngII plays a number of
roles in vascular pathology, and was thought to exert its effects by inducing nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase and increasing cellular reactive
oxygen species (ROS).19 In turn, ROS stimulate the expression of BMP2 and the
osteoblast transcription factor Cbfα1/Runx2, thereby inducing osteoblast
transdifferentiation.46 The first evidence that AngII affected calcification in VSMCs was
from Jaffe and Mendelsohn,55 who suggested it (along with aldosterone) acted through
the mineralocorticoid receptor to promote fibrosis and calcification.56 More recently, an
in vitro study by Jia et al.57 showed that AngII promoted vascular calcification via Cbfα1/
Runx2 and nuclear factor κB (NF-κB). The receptor activator of NF-κB (RANKL) and
BMP2 axis has been long implicated in arterial calcification, and a subsequent study
suggested that AngII induced vascular calcification in vitro and in vivo via RANKL
activation. In turn, RANKL promoted ACE and AT1R, members of the RAS pathway,
creating a feedback loop.58

1.2.4 Clinical Implications
There is evidence to suggest that arterial calcification, at least in the peripheral arteries,
may affect 30–50% of asymptomatic patients in the United States.59 In patients with
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CKD, arterial calcification tends to be more advanced and is associated with increased
morbidity and mortality.60-63 Indeed, the leading cause of death in CKD patients is
cardiovascular disease.64 In patients with non-insulin-dependent DM, arterial calcification
is a strong independent predictor of total, cardiovascular, and coronary heart diseaserelated mortality. It is also associated with increased risk for MI, stroke, and amputation.
7,65

Tibial artery calcium score also predicts the short-term risk of amputation in patients

with peripheral artery disease.66 There is also some evidence to suggest that calcification
of small blood vessels can lead to necrosis and ulceration of the skin.67,68 Clearly, arterial
calcification is prevalent in Western society and in dire need of preventive therapy.

1.2.5 Pharmaceutical Management
Blockade of the RAS has been shown to reduce morbidity and mortality in patients with
hypertension, atherosclerosis, heart failure, stroke, DM, and CKD,69-73 often independent
of changes in blood pressure.69,71,73,74 To date, there have been no clinical studies
examining the role of RAS blockade on arterial calcification. However, pre-clinical
studies do provide some encouraging evidence. Recent studies have shown that ACEIs –
specifically, perindopril and captopril – can prevent the progression of arterial
calcification in rat models of CKD56,75 and hypertension.76 An older study in a 5/6
nephrectomized rat model found that enalapril could not suppress arterial calcification
but did decrease mortality.77 The ARB irbesartan has also been shown to prevent arterial
calcification in a rat model of hypertension as long as therapy is initiated alongside insult,
which in this case was warfarin and vitamin K1.78 Irbesartan is also capable of blocking
AngII-induced expression of BMP2 in human endothelial cells.79
The effects of other pharmaceuticals have also been examined in relation to arterial
calcification, with some success. The calcium channel blocker amlodipine, another
antihypertensive, was able to induce regression of arterial calcification in a pre-clinical
model.80 The endothelin receptor antagonist darusentan may also be able to induce
regression.78,81 Interestingly, there is some evidence to suggest that osteoporosis
therapies, including bisphosphonates, may provide benefit to patients with arterial
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calcification.82 Ultimately, however, no pharmaceuticals are clinically indicated for the
specific prevention of arterial calcification.

1.3 Intimal Calcification
Intimal calcification occurs within the cholesterol-rich lesions characteristic of
atherosclerosis which can result in MI, stroke, or limb ischemia (Figure 1.1). Commonly
associated with old age, male sex, hypertension, smoking, and hypercholesterolemia,83
intimal calcification is a reliable marker of plaque burden84,85 and may contribute to
plaque instability.86

1.3.1 Initiation and Progression of Atherosclerosis
Atherosclerosis is a chronic, progressive disease of the vascular system. In areas
predisposed to atherosclerosis, variations in hemodynamic forces can result in adaptive
intimal thickening defined as an increase in SMCs and extracellular matrix lacking any
inflammatory infiltrate.87 The initial atherosclerotic plaque (Type I or II), appearing in
those as young as age 2,88 is described as a fatty streak or a visible accumulation of lipidladen macrophages (foam cells) and is capable of regressing naturally.89 The advanced
atherosclerotic plaque (Type IV, V, or VI), or fibroatheroma, is characterized by a lipidrich necrotic core covered by a SMC-rich fibrous cap.90 The rupture of these advanced
plaques can lead to either downstream arterial occlusion or localized thrombus formation
and subsequent ischemic death of the tissue supplied.

1.3.2 The Vulnerable Plaque
The difference between a stable and a vulnerable plaque is primarily related to the
thickness and composition of the fibrous cap. The concept of a vulnerable plaque, or a
plaque that is prone to rupture, was first introduced by Muller and Tofler.91 The
vulnerable plaque was described as having a lipid-rich necrotic core and a generally thin
fibrous cap,92 until Burke et al.93 refined the classification to those plaques with a fibrous
cap less than 65 µm thick. They also noted that the fibrous cap of vulnerable plaques
often had macrophage infiltration and a loss of SMCs, characteristics which would
certainly promote fibrous cap degradation and plaque rupture.94
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1.3.3 Initiation and Progression of Calcification in Atherosclerosis
Calcification of the atherosclerotic plaque begins as micro-calcifications, typically less
than 15 µm in diameter.95,96 Micro-calcifications are present in all types of lesions,
including fatty streaks, and their abundance increases as atherosclerosis advances.97,98
They also precede the appearance of the bone-promoting proteins BMP2 and OCN which
suggests that, at least initially, the calcification process in atherosclerotic plaques is
distinct from typical bone formation.98 Micro-calcifications may be initiated by matrix
vesicles of apoptotic SMCs99-101 or macrophages (Figure 1.3).95,102 Once initiated, there is
evidence to suggest a highly regulated process which involves several bone-related
proteins that promote (BMP2, BMP4, osteopontin, and osteonectin) and inhibit (matrix
gla-protein and bone sialoprotein) atherosclerotic calcification.103-106 Furthermore, the
mineral composition of calcific atherosclerotic plaques is chemically similar to that
observed in bone.107-111

1.3.4 Calcification and Vulnerability
There is controversy as to whether plaque calcification stabilizes advanced lesions or
promotes rupture. Generally, the presence of calcification is correlated with the incidence
of cardiovascular disease,112 and is associated with increased atherosclerosis progression.
85,113

While some have reported an association between calcification and stability,114,115

others suggest calcification is a marker of vulnerability86,116 and may even promote
rupture.94 These disparate reports suggest that the localization of calcification, rather than
the volume, may be an important indicator of plaque vulnerability. Indeed, an
intravascular ultrasound study suggested that calcification near the base of the lesion
increased stability,117 and a mathematical modeling study suggested that calcification in
the fibrous cap may as well.118 However, several studies have suggested that microcalcifications within the fibrous cap directly promote plaque rupture.95,96,119 Taken
together, these reports suggest that the relationship between calcification and plaque
rupture is biphasic. Abedin et al.120 argue that the principal site of stress is the interface
between hard, calcified areas and soft, cellular areas within the plaque; therefore, stress
would initially increase as calcification increases until such time that individual calcified
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areas enlarge and coalesce, thereby reducing interface area and overall stress. This
argument was validated by Motoyama et al.,121 who observed spotty calcification more
frequently in ruptured plaques from acute coronary syndrome patients than stable ones
from angina pectoris patients. Conversely, they observed large calcification more
frequently in stable plaques.122 Clearly, a deeper understanding of the processes
underlying atherosclerotic calcification and its relationship to vulnerability is required.

1.3.5 Clinical Implications
For almost a century, cardiovascular disease has accounted for more deaths than any
other major cause in the United States, and a majority of these deaths are a result of
atherosclerosis.83 Coronary arterial calcification is present in 52.9% of men and 32.0% of
women over the age of 45, and its severity is predictive of overall cardiovascular risk.123
Obviously, the acute clinical implications of atherosclerosis depend on the location of
individual vulnerable plaques. Rupture of a plaque in the coronary arteries or the carotid
can lead to MI or stroke, respectively. Furthermore, the implications of intimal
calcification rely on its relationship to plaque vulnerability. This is an area that requires
considerably more study, including a reliable mechanism for blockade of calcification.

1.3.6 Pharmaceutical Management
Current clinical guidelines recommend an LDL-cholesterol goal of less than 100 mg/dL
in patients at risk for cardiovascular disease,124,125 and statins play a role in achieving that
goal. Statins, or 3-hydroxy-3-methylglutaryl Co-enzyme A (HMG-CoA) reductase
inhibitors, inhibit the rate limiting enzyme in endogenous cholesterol production and thus
are frontline drugs for the management of hypercholesterolemia. It is well known that
statins reduce the incidence of cardiovascular events,126 including MI and stroke,127 and
studies have shown that statins alter the progression of subclinical atherosclerosis. Statins
are effective at reducing atherosclerotic lesion volume,128-132 reducing the size of the lipid
core,133 and reducing progression of carotid intima-media thickness.134,135 Pre-clinical
models have provided more information about the specific effects of statins, including
pleiotropic effects (those not related to cholesterol-lowering). Statins have been shown to
reduce expression of monocyte chemotactic protein-1, intercellular adhesion molecule-1,
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and vascular cell adhesion molecule-1,136,137 down-regulate cyclooxygenase 2,138 improve
nitric oxide bioavailability,139 suppress oxidation of LDL140, and reduce the overall
inflammatory burden within atherosclerotic plaques.141 The effects of statins on intimal
calcification have not been thoroughly examined, although Kizu et al.142 showed that
cerivastatin could inhibit calcification of VSMCs in vitro. In contrast, a recent clinical
study found progression of coronary calcium was significantly higher in frequent statin
users versus those who used statins infrequently.143
Inhibition of the RAS may also have benefits in atherosclerosis. Three of the four
prospective clinical trials examining the effect of ARBs on cardiovascular outcomes
showed little144 or no145,146 benefit; however, the OLIVUS (Impact of OLmesartan on
progression of coronary atherosclerosis: evaluation by IntraVascular UltraSound) trial
found a lower rate of coronary atherosclerosis progression and decreased incidence of
major adverse cardio- and cerebrovascular events in patients treated with olmesartan.
147,148

More recently, Zhao et al.149 showed that telmisartan reduced plaque size,

macrophage infiltration, lipid deposition, and apoptosis in atherosclerotic plaques in a
pre-clinical model. Three clinical trials examining ACEIs showed improved
cardiovascular outcomes;70,150,151 however, two more recent trials showed no benefit.
152,153

Recently, meta-analysis suggested that ARBs and ACEIs reduce the incidence of

cardiovascular death, non-fatal MI, and non-fatal stroke, even in normotensive
atherosclerosis patients.154 Other clinical studies have shown that ARBs reduce plaque
volume155 and decrease inflammation.156 A pre-clinical study in monkeys also observed a
regressive effect of ARBs, albeit on fatty streaks.157 Interestingly, aliskiren, a renin
inhibitor, was associated with increased progression of atherosclerosis.158
There have also been a number of studies examining various combinations of statin
therapy and RAS blockade. Several pre-clinical studies examining statins in combination
with ARBs have found an additive reduction of atherosclerosis burden in mice159-161 and
rabbits.162,163 Another pre-clinical study examined the effects of simvastatin and a
peroxisomal proliferator-activated receptor-gamma (PPARɣ) agonist and showed that the
addition of PPARɣ agonist provided an additive benefit to atherosclerotic plaque
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regression;164 which is of particular interest since some ARBs have been shown to have
PPARɣ agonist activity.165-167
It remains unclear whether aggressive medical management of intimal calcification will
provide a reduction in cardiovascular events. However, improving our understanding of
the mechanisms underlying calcification could provide an opportunity to prevent it
which, in turn, could help reveal its relationship to plaque vulnerability.

1.4 Calcific Aortic Valve Disease
Calcific aortic valve disease, encompassing early aortic valve sclerosis (AVS) and clinical
aortic stenosis, results in calcification of the aortic valve cusps and hardened, non-pliable
valve tissue, decreased orifice area, and increased aortic jet velocity (Figure 1.1).168
Commonly associated with old age, male sex, hypertension, smoking, increased plasma
LDL, increased plasma lipoprotein (a), and DM,13,20,169-178 calcific aortic valve disease is
associated with an increased risk of MI and cardiovascular death.13-16

1.4.1 The Aortic Valve
The normal human aortic valve has a three-layered structure measuring 1 mm in
thickness169,179 with the fibrosal layer on the aortic side, the ventricularis on the
ventricular side, and the spongiosa centrally (Figure 1.1). The fibrosa primarily contains
highly organized collagen bundles between which lie valvular interstitial cells (VICs).
The ventricularis is less organized and generally less cellular; it contains elastin sheets
and some collagen. In contrast, the spongiosa is rich in cells and proteoglycans, but
contains little collagen.

1.4.2 Calcific Aortic Valve Disease
A chronic progressive disease, AVS is characterized by five factors: endothelial
dysfunction, lipid deposition, chronic inflammation, activation of a local RAS and
eventually, tissue calcification. The development of AVS results in distinctive anatomical
changes first described by Otto et al.169 as sub-endothelial thickening and fibrosis,
disruption of the basement membrane, and accumulation of both intra- and extra-cellular
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lipids. In the same year, Olsson et al.171 independently reported large numbers of
activated T-lymphocytes located in subendothelial areas in close proximity to calcium
deposits.
The initiating event in AVS appears to be endothelial cell activation in areas of
mechanical stress, thereby predisposing the tissue to infiltration by plasma lipoproteins,
180,181

a course similar to the development of atherosclerosis (Figure 1.3). In the aortic

valve, lipid deposition tends to be localized to the fibrosa where it co-localizes with
components of atherogenic apolipoproteins.170,182 Over time, lipid particles become
oxidized and are taken up by infiltrating macrophages to form foam cells.169,171 Oxidized
LDL is highly cytotoxic for many cells including endothelial cells and VICs; in addition,
native LDL has been shown to co-localize with ACE both in human plasma and aortic
valve lesions,20 creating an environment for the local production of AngII. More recently,
Helske et al.29,30 described the participation of two additional AngII-forming enzymes:
mast cell-derived chymase and cathepsin G.

1.4.3 Angiotensin II in Aortic Valve Disease
The pro-inflammatory and pro-fibrotic effects of AngII are well understood183 and are
often cited as its main contribution to AVS.184-186 It is likely, however, that AngII is
affecting all aspects of aortic valve disease, including lipid retention, inflammation,
endothelial integrity, and calcification. In cardiac fibroblasts and VSMCs, AngII has been
shown to induce the production of biglycan, a proteoglycan with enhanced LDL binding
properties.187,188 Production of biglycan in aortic valves would promote retention of LDL
and associated ACE, creating a positive feedback loop for AngII production. Blockade of
AngII improves endothelial integrity in a rabbit model of AVS, and also up-regulated
endothelial nitric oxide synthase, an enzyme that is generally considered to be
cardioprotective.189 Most importantly, AngII has been shown to transactivate NADPH
oxidase in VSMCs, leading to production of ROS. In turn, ROS have been shown to
promote vascular calcification,190 and specifically localize around calcifying foci in
human aortic valves.191
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1.4.4 Clinical Implications
The prevalence of AVS is estimated to be 25–30% in those over age 65 and up to 40% in
those over age 75,4,192 typically progressing to severe aortic stenosis in 6% of patients
over a period of 7 years.193 Even early AVS without concomitant coronary artery disease
is predictive of a 50% increase in cardiovascular death.13 Considering that the primary
cause of valve failure is extensive calcium deposits, it is no surprise that calcified volume
correlates with the severity of AVS194 and is associated with the incidence of coronary
events and all-cause mortality.195-197

1.4.5 Pharmaceutical Management
Once AVS is initiated, increased physical activity or a change in diet is not sufficient to
alter the disease process.198 However, an excellent environment exists for preventive,
pharmaceutical management. The average time interval from subjective diagnosis of AVS
to the development of severe stenosis is eight years,193,199 and it is increasingly clear that
intervention should start as early as possible.200
The overlap in clinical factors associated with AVS and atherosclerosis had suggested a
shared disease process,201 thus the demonstrable benefits of statins on atherosclerosis
provided support for their use in AVS. Several pre-clinical studies also promoted the
effectiveness of statins for inhibiting hypercholesterolemia-induced cellular
proliferation202 and calcification.203,204 In all, twelve clinical studies have evaluated the
role of statins on AVS progression but the results have been conflicting.205-216 Six small
retrospective studies, with a mean follow up of 6–44 months, showed a lower rate of AVS
progression in patients treated with statins.205-209,211 Conversely, a larger retrospective
study with a mean follow up of 66 months did not observe slower progression.210 Five
prospective trials observed little213 or no212,214-216 effect of statins on the progression of
AVS. The SEAS (intensive lipid lowering with Simvastatin and Ezetimibe in Aortic
Stenosis) trial was the largest to date and the only one to measure clinical outcomes.
Patients treated with simvastatin and ezetimibe showed a decrease in ischemic cardiac
events but there was no effect on outcomes related to the aortic valve.215 Hamilton et al.
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217

confirmed the ineffectiveness of statins in a pre-clinical model, observing a reduction

of inflammation but retention of lipids and the continuation of calcium deposition.
Compared to statins, blockade of the RAS has received relatively little clinical
examination as a preventive therapy for AVS. A retrospective study found that ACEIs
could not slow the increase in aortic jet velocity associated with AVS;209 however, a
separate retrospective study, specifically examining aortic valve calcium, showed a
significant reduction in progression.218 The ACEI ramipril was effective in reducing
progression of AVS,219 and the ARB olmesartan has been shown to reduce atherosclerotic
changes and endothelial disruption in short-term animal models;189 however, neither
study examined effects on calcification. More recently, a clinical study of excised aortic
valves observed lower remodeling scores and decreased weight in those valves from
patients who had been treated with ARBs.220,221 A retrospective study compared the
effects of ARBs and ACEIs on AVS and found that only ARBs were effective at reducing
progression.222 A small clinical study of the aldosterone receptor blocker epleronone
showed no effect on AVS,223 but a pre-clinical study examining the early stages of the
disease suggested some effects, including a small, qualitative reduction in microcalcification.224
There has been limited examination of other potential therapies for AVS. In an
observational clinical trial, a cohort of patients receiving osteoporosis therapy –
bisphosphonates, calcitonin, or estrogen receptor modulators – had a lower rate of AVS
progression.225 A pre-clinical trial also had success with bisphosphonates, suggesting they
are able to robustly inhibit valve calcification.82 An experimental recombinant
apolipoprotein, Apo-A1Milano, was successful in reversing AVS in a pre-clinical model,
including a qualitative reduction of micro-calcification.226
To date, clinical guidelines provide no recommendation for the managements of AVS,
suggesting additional trials with patients earlier in the disease continuum and with longer
follow-up periods are required.168 In addition, the multitude of mechanisms involved in
the progression of AVS suggests that drug therapy may have to be multifactorial.227
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1.5 Study Rationale and Hypothesis
In summary, little is known about the mechanisms driving cardiovascular calcification
despite serious clinical implications and a clear association with morbidity and mortality.
Indeed, it is even unclear whether the same mechanisms are at play in arterial, intimal,
and valvular calcification. There is some evidence to suggest that the RAS and its
vasoactive agent, AngII, are involved in promoting cardiovascular calcification; however,
ARBs have not been robustly examined as potential therapies. As such, we set out to test
the hypothesis that the ARB olmesartan medoxomil inhibits progression of established
cardiovascular calcification in vivo.

1.6 Objectives and Future Directions
1.6.1 Investigate Effects of an ARB on Arterial Calcification in a PreClinical Model
In Chapter 2, a version of which has been published in Cardiovascular Research,228 we
use New Zealand White rabbits to investigate the effects of the ARB olmesartan
medoxomil on established arterial calcification. This pre-clinical model has been used
successfully by others to investigate potential pharmaceutical therapies.229 Using microcomputed tomography (micro-CT), histology, and immunohistochemistry, we are the first
to show robust inhibition of arterial calcification by an ARB. Calcified areas in our
animals displayed a down-regulation of α-smooth muscle actin, a smooth muscle cell
marker; up-regulation of BMP2 and the ATIR; and expression of the osteoblast-specific
protein OCN.

1.6.2 Investigate Effects of an ARB on Intimal Calcification in a PreClinical Model
In Chapter 3, a version of which has been submitted for publication in the Canadian
Journal of Cardiology, we use New Zealand White rabbits to investigate the effects of the
ARB olmesartan medoxomil, alone or in combination with atorvastatin, on established
atherosclerosis and intimal calcification. The long-term, low-level cholesterol rabbit
model we employed for this study was developed previously by our lab and has been
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shown to produce significant atherosclerosis over a period of six months with 58% of the
aortic surface covered by atheroma and up to 75% of those lesions considered to be
advanced.230,231 Previous examination of these lesions revealed their similarity to human
atherosclerosis; VSMCs and collagen extracellular matrix formed a fibrous cap over a
core of lipids, cholesterol crystals, and necrotic debris.231 Using classical lesion area
analysis, micro-CT, histology, and immunohistochemistry, we show a significant
reduction of atherosclerotic burden in animals treated with ARB monotherapy, but not in
combination therapy (ARB+Statin). In addition, both ARBs and statins may have slowed
progression of intimal calcification.

1.6.3 Investigate Effects of an ARB on Calcific Aortic Valve Disease in
a Pre-Clinical Model
In Chapter 4, a version of which has been accepted for publication in the Canadian
Journal of Cardiology,232 we use the same animals as in Chapter 3 but examine the
effects of the ARB olmesartan medoxomil, alone or in combination with atorvastatin, on
established calcific aortic valve disease. Previously, Cimini et al.233 examined the
development of calcific aortic valve disease in our long-term, low-level cholesterol rabbit
model.230,231 Rabbits have been shown to develop aortic valve thickening, inflammation,
and lipid deposition over a period of ten months. While calcification was not observed in
the initial report, it was present in aortic valves after 30 months of cholesterol feeding.217
We did not observe any demonstrable treatment effects using in vivo magnetic resonance
imaging. However, ex vivo histological and immunohisochemical analyses revealed
structural changes to the aortic valve. In particular, ARB-treated animals had significantly
increased levels of valvular calcification.

1.6.4 Conclusions and Future Directions
Finally, in Chapter 5, I summarize the results and conclusions of my work. Namely, the
disparate effects of the ARB in treating arterial, intimal, and valvular calcification suggest
distinct cellular and molecular mechanisms are at play in each disease process. More
work needs to be done to fully understand these differences but the robust inhibitory
effect of the ARB on arterial calcification cannot be ignored. Therefore, I suggest a
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prospective, randomized trial in patients with chronic kidney disease, a group prone to
rapid development of arterial calcification. Such a trial would be valuable, given there is
currently no preventive therapy for arterial calcification. In all, the studies herein have
advanced our understanding of cardiovascular calcification and, together with future
work, may lead to novel therapies.
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Chapter 2

2

Angiotensin II Type 1 Receptor Blocker Inhibits Arterial
Calcification in a Pre-Clinical Model*

Arterial calcification, also known as Mönckeberg sclerosis, involves mineralization of the
internal elastic lamina (IEL) and elastic fibers within the medial layer resulting in
hardened arteries and increased pulse pressure. Commonly associated with advanced age,
chronic kidney disease, diabetes mellitus, and atherosclerosis, arterial calcification is
closely related to cardiovascular morbidity and mortality.1-3 In the past, it was considered
a passive, degenerative and, most importantly, irreversible process.4 More recently, it has
become clear that this process is highly regulated, involving a number of pro- and anticalcification mediators, and resembles natural bone formation.5 Indeed, a recent study by
Speer et al.6 has shown that vascular smooth muscle cells (SMCs) are capable of
osteoblast transdifferentiation in calcifying arteries. This transdifferentiation was
associated with downregulation of SMC markers and concomitant upregulation of the
osteoblast transcription factor Runx2/Cbfα1. Although tremendous progress has been
made in this area, the molecular mechanisms underlying this process remain to be fully
defined.
There is growing evidence that vasoactive agents are important modulators of vascular
calcification. Naturally existing peptides such as endothelin-1 and urotensin II can
promote arterial calcification, while others – adrenomedullin and C-type natriuretic
peptide – act to inhibit its progression.7-9 However, the role of the renin-angiotensin
system (RAS) and its vasoactive agent, angiotensin II (AngII), has not been investigated.
AngII plays a number of roles in vascular pathology, and is thought to exert its effects by
inducing NADPH oxidase and increasing cellular reactive oxygen species (ROS).10 In
turn, ROS stimulate the expression of bone morphogenetic protein (BMP) 2 and the
osteoblast transcription factor Runx2/Cbfα1, thereby inducing osteoblast
transdifferentiation.11 Blockade of RAS has been shown to reduce morbidity and
A version of this chapter has been published: Armstrong ZB, Boughner DR, Drangova M, Rogers KA.
Angiotensin II type 1 receptor blocker inhibits arterial calcification in a pre-clinical model. Cardiovasc Res
2011;90:165-70.
*
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mortality in hypertension, atherosclerosis, heart failure, stroke, diabetes, and chronic
kidney disease,12-17 often independent of changes in blood pressure.12,14-15,17
Here, we test the hypothesis that an angiotensin II type 1 receptor blocker (ARB) can
inhibit arterial calcification in vivo. We also further characterize the mechanism by which
vascular calcification occurs using immunohistochemical methods.

2.1 Methods
2.1.1 Pre-Clinical Model
Male New Zealand White rabbits (1.6 to 2.0 kg, Charles River Laboratories, St-Constant,
QC) were fed either regular chow (Control; n = 9) or an atherogenic diet (Cholesterol; n
= 9) consisting of 0.5% cholesterol and 10,000 IU/day Vitamin D2 for 12 weeks to
rapidly induce atherosclerosis and arterial calcification. The treatment group (ARB; n =
6) received the atherogenic diet for 12 weeks with the ARB olmesartan medoxomil (1
mg/kg/day) in the final 4 weeks. Olmesartan medoxomil, suspended in 60% molasses,
was administered daily via oral gavage. Vitamin D2 and its analogs have been used
extensively to induce vascular calcification in animal models,18 and there is controversy
as to whether or not it contributes to vascular calcification in humans.19 After 8 weeks, a
subset of the Control (n = 3) and Cholesterol fed (n = 3) groups were euthanized to assess
lesion progression at the time of pharmacological intervention. At twelve weeks, animals
were euthanized via intravenous ketamine injection and perfused with Hank’s balanced
salt solution and heparin (1 U/mL). Immediately upon dissection the thoracic aorta was
fixed in 10% neutral buffered formalin. The investigation conforms with the Guide for
the Care and Use of Laboratory Animals published by the US National Institutes of
Health (NIH Publication No. 85-23, revised 1996). All animal protocols were approved
by the University of Western Ontario Animal Use Subcommittee (reference number
2007-023).

2.1.2 Plasma Chemistry
Blood samples were obtained for the measurement of total cholesterol and inorganic
phosphate. EDTA was used in the isolation of plasma, preventing analysis of calcium.
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Total cholesterol was measured at weeks 0, 4, 8, 10, and 12 (endpoint) using a WAKO
Cholesterol E Kit, according to the manufacturer’s instructions. Inorganic phosphate was
examined at endpoint using standard autoanalyzer methods at the London Health
Sciences Centre Core Laboratory (London, ON, Canada).

2.1.3 Micro-Computed Tomography
Thoracic aortae were placed in a humidified chamber to prevent dehydration and scanned
with an eXplore Locus micro-computed tomography (micro-CT) scanner (General
Electric Medical Systems, London, Ontario). Scans were acquired at 80 kVp, 130 mAs
and reconstructed with isotropic voxel spacing of 90 µm. Images were analyzed for the
presence of calcium using MicroView analysis software (V2.2, GE Medical Systems,
London, Ontario). Specifically, the total volume of all voxels containing calcified tissue
(identified by setting a threshold level) was calculated and expressed as percent of total
vessel volume.

2.1.4 Histological and Immunohistochemical Analysis
Thoracic aortae were embedded in Tissue-Tek OCT compound and frozen in liquid
nitrogen-cooled isopentane. Frozen sections (10 µm) were taken as cross-sections through
the aorta distal to the first intercostal ostia. Serial sections were stained with Alizarin Red
S and von Kossa for calcium deposition. Immunohistochemical studies were performed
using the following primary antibodies: mouse anti-α-smooth muscle actin (clone 1A4),
mouse anti-angiotensin II type 1 receptor (clone 1E10-1A9), mouse anti-BMP2 (clone
1A11), mouse anti-osteocalcin (clone OC4-30), mouse anti-osteopontin (clone
MPIIIB10), and mouse anti-rabbit activated macrophage (clone RAM11). Sections were
subjected to single label immunohistochemistry using an Alkaline Phosphatase Substrate
Kit (Vector Laboratories) and secondary antibody horse anti-mouse IgG (H + L) Alkaline
Phosphatase-conjugate according to the manufacturer’s instructions. Negative controls
which omitted the primary antibody were routinely employed.
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2.1.5 Statistical Analysis
Data are expressed as mean ± SEM. All analyses were performed using GraphPad Prism
(V4.0, GraphPad Software, La Jolla, CA, USA). Statistical analyses were performed
using a Kruskal-Wallis test with Dunns post-hoc test, or one-way repeated measures
ANOVA with Tukey’s post-hoc test, as appropriate. P < 0.05 was considered statistically
significant.

2.2 Results
2.2.1 Animals and Plasma Chemistry
A subset of Control (n = 3) and Cholesterol (n = 3) animals were euthanized after 8
weeks to assess the extent of disease before administration of the ARB (Supplementary
Figure 2.1). A single ARB-treated rabbit died due to unknown causes after a week of
treatment (9 weeks total) and was not included in the analysis. To assess systemic effects
of ARB treatment we examined plasma levels of total cholesterol and inorganic
phosphate. While total cholesterol levels were significantly increased in Cholesterol
animals as compared to Control (1394.00 ± 352.16 versus 15.49 ± 6.31 mg/dL in
Cholesterol and Control, respectively; n = 6/group; P < 0.001) there was no significant
effect of ARB treatment (1531.18 ± 334.51 mg/dL; n = 5; P < 0.001 versus Control; P =
ns versus Cholesterol; Supplementary Figure 2.2A). Levels of inorganic phosphate were
the same in all groups (3.43 ± 0.17, 4.38 ± 0.40, and 3.83 ± 0.87 mg/dL in Control,
Cholesterol, and ARB, respectively; n = 5, 6, and 4; P = ns; Supplementary Figure 2.2B),
and within the normal physiological range for New Zealand White rabbits.

2.2.2 Arterial Calcification is Abolished After Treatment with the ARB
To evaluate the effects of ARB treatment on arterial calcification we administered
olmesartan medoxomil for the final four weeks of the twelve-week protocol. Calcification
was significantly increased in Cholesterol animals (non-detectable versus 2.80 ± 1.17 %
calcified tissue in Control and Cholesterol, respectively; n = 6/group; P < 0.01) and, in
contrast, was completely inhibited in all but one ARB-treated animal (0.01 ± 0.01 %
calcified tissue in ARB; n = 5; P < 0.05 versus Cholesterol; Figure 2.1A). Calcification,
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Figure 2.1: Treatment with the angiotensin II type 1 receptor blocker (ARB)
inhibited arterial calcification. (A) Representative maximum intensity projections,
derived from micro-computed tomography (CT) scans, and corresponding quantitation of
Control (n = 6), Cholesterol (n = 6) and ARB (n = 5) animals reveals a significant
increase in arterial calcification after 12 weeks on the atherogenic diet, except in ARBtreated animals where no significant calcification was detected. Scale bar = 4 mm.
Kruskal-Wallis test with Dunns post-hoc test: *p < 0.01 versus Control. †p < 0.05 versus
Cholesterol. (B) Histological examination of calcium (Alizarin Red S, top) and calcium
salts (Von Kossa, bottom) reveals that they are localized primarily to the internal elastic
lamina (IEL) and medial layer, typical of arterial calcification. Scale bar = 500 µm. ND =
none detected. Arrows indicate calcification.
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when present, was primarily localized to the IEL and media (Figure 2.1B). Some animals
(3 of 6 Cholesterol, 2 of 5 ARB) exhibited micro-calcifications within atherosclerotic
plaques (Figure 2.2) either in addition to, or independent of, IEL/media calcification. It
should be noted that the calcification found in the ARB-treated animals was minor (< 10
µm in size) and was localized to the plaque. These calcifications were too small to be
detected by micro-CT because their signal was masked by the surrounding tissue, which
occupied the majority of the 90 µm3 voxel.

2.2.3 Calcified Regions Express the Bone-Related Proteins BMP2
and Osteocalcin and Dramatically Increase Expression of
the AT1R
To gain insight into the mechanisms underlying this calcification process, we
characterized the calcified regions using immunohistochemical methods. Adjacent
sections acted as negative controls (omission of primary antibody) and showed no
positive staining (data not shown). Calcified areas, and the tissue immediately
surrounding them, showed expression of the osteogenic growth factor BMP2 (Figure
2.3). Calcified areas also exhibited increased expression of the bone protein and
osteoblast-specific marker osteocalcin (Figure 2.3).22 In addition, calcified areas display
dramatic upregulation of the angiotensin II type 1 receptor (AT1R; Figure 2.3), which has
been shown to increase in expression as osteoblasts mature. Calcified areas also showed
limited expression of the calcium binding protein osteopontin (data not shown).
Corresponding low power images can be found in Supplementary Figure 2.3. Taken
together, this strongly suggests the presence of osteoblasts within areas of calcification.

2.2.4 Calcified Areas of the Media are not Associated with SMCs or
Macrophages
To eliminate other possible cell types within calcified areas, we examined the expression
of α-smooth muscle actin, a marker of smooth muscle cells, and RAM11 as a marker of
macrophages. Calcified areas were associated with a downregulation of α-SMA (Figure
2.4). In addition, some areas not associated with calcification also displayed
downregulation of α-SMA (Supplementary Figure 2.4), possibly indicating initial
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Figure 2.2: Arterial calcification versus micro-calcification of atherosclerotic
plaques. Animals fed the atherogenic diet primarily displayed calcification of the IEL
and medial layer (arrows). However, histological examination revealed that a number of
animals (3/6 Cholesterol, 2/5 ARB) exhibited micro-calcifications within atherosclerotic
plaques (arrowheads). It is important to note that these are generally considered distinct
processes, and that the minor calcification displayed in the ARB animals was localized to
the plaque. Scale bar = 500 µm and 100 µm (inset). Abbreviations as in Figure 2.1.
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Figure 2.3: Characterization of calcified regions indicates an osteoblast-like
phenotype. Immunohistochemical characterization of calcified regions (arrows) and
adjacent sections reveals colocalized expression of the osteogenic growth factor bone
morphogenetic protein 2 (BMP2), the bone protein and osteoblast-specific marker
osteocalcin (OCN), and dramatic upregulation of the angiotensin II type 1 receptor
(AT1R). This data suggests an osteoblast-like phenotype within calcified areas. Scale bar
= 500 µm.
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Figure 2.4: Calcified regions of the media are not associated with smooth muscle
cells or macrophages. Examination of α-smooth muscle actin (α-SMA), a marker of
smooth muscle cells, reveals dramatic downregulation in calcified regions (arrows).
Furthermore, macrophages are localized specifically to atherosclerotic plaques, and are
not associated with areas of calcification. Scale bar = 500 µm.
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progression toward an osteogenic phenotype. Interestingly, some of these areas also
showed upregulation of BMP2 (data not shown). Macrophages were localized
specifically to atherosclerotic lesions and were not observed within the medial layer
(Figure 2.4). Corresponding low power images can be found in Supplementary Figure
2.4. Taken together, this suggests a phenotypic switch from vascular to osteoblast-like
cells.

2.3 Discussion
The present study is the first to show the dramatic inhibition of arterial calcification by an
ARB. Using micro-CT and histology, we have shown that ARB administration, given
after induction of disease, can robustly inhibit the calcification observed in animals not so
treated. While others have used doses of 25,000-50,000 IU/day Vitamin D2,23-24 we
achieved significant levels of vascular calcification in the same time period using 10,000
IU/day. The calcification we observed was localized to the IEL and medial layer, typical
of Mönckeberg sclerosis as well as vascular calcification associated with chronic kidney
disease and diabetes mellitus.20-21 In chronic kidney disease, up to 55% of deaths are
cardiovascular related, and cardiovascular mortality is 10-100 times greater than that for
age-matched populations.25 In type 2 diabetes, arterial calcification is a strong predictor
of mortality and lower extremity amputation.26-27 Inhibiting progression of arterial
calcification remains the goal of several groups,6,28-32 but it is generally thought to be
irreversible. In contrast, at least one group has shown reversibility of vascular
calcification in rats with normal renal function.33 Here, we provide the first evidence that
an ARB is capable of halting progression of arterial calcification.
While the underlying pathologies (diabetes, chronic kidney disease, advanced age) are
distinct, the process ultimately leading to vascular calcification is related. Although
vascular SMC transdifferentiation to osteoblasts is under intense investigation,33-37 the
molecular mechanisms are not fully understood. Characterization of the calcific lesions
we observed suggests that they result from such a transition. Expression of BMP2, an
osteogenic growth factor, in the areas in and around calcification suggests that it is
involved in directing this transition, as others have suggested.38 Calcified areas display
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expression of the bone-associated proteins osteopontin and OCN. Osteopontin can be
expressed by a range of cell types, including bone cells and macrophages, and has been
shown to contribute to arterial calcification.39 Osteocalcin, an osteoblast-specific marker,
is often used as a biomarker for bone formation, and is also implicated in calcium ion
homeostasis.22 Calcified regions also displayed marked upregulation of the AT1R. The
AT1R is commonly expressed in the vasculature, and is responsible for mediating
signaling of the RAS. Indeed, we observed diffuse staining for AT1R in aortas from all of
our animals. However, recent work by Bandow et al.40 has shown that osteoblasts, as they
mature, greatly increase expression of the AT1R. We observed regional upregulation of
the AT1R in areas associated with calcification, again suggesting an osteoblast-like
phenotype. Furthermore, calcified areas showed dramatic downregulation of α-SMA, a
smooth muscle marker, providing evidence for a phenotypic switch from vascular to
osteoblast-like cell. Here, we provide the first evidence that the RAS is involved in
vascular osteogenesis, and that an ARB is capable of modulating the process.
Despite the dramatic effect on calcification, ARB therapy had no effect on systemic
disease indicators (hypercholesterolemia and hyperphosphatemia), suggesting its effects
are specific to the vascular system, rather than a result of secondary phenomena. As
expected, ARB therapy did not normalize total cholesterol.41-42 There was also no effect
on plasma levels of inorganic phosphate, either by the atherogenic diet or by ARB
therapy. It is important to note that we were unable to reliably quantify changes in the
extent of atherosclerosis, as extensive calcium deposition in Cholesterol animals
prevented both ultrasound examination and en face lipid staining.
Here, we show that angiotensin receptor blockade robustly inhibits the progression of
arterial calcification. This form of calcification, commonly associated with advanced age,
chronic kidney disease, and diabetes mellitus, is a result of osteoblast transdifferentiation
of vascular cells,6 a process replicated here in a pre-clinical model. This study is the first
to suggest ARB therapy as a novel treatment option for patients at risk for cardiovascular
calcification.

63

2.4 References
1.

Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial
calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease.
Hypertension 2001;38:938–42.

2.

Jeffcoate WJ, Rasmussen LM, Hofbauer LC, Game FL. Medial arterial
calcification in diabetes and its relationship to neuropathy. Diabetologia
2009;52:2478–88.

3.

Takasu J, Budoff MJ, Katz R, Rivera JJ, O'Brien KD, Shavelle DM, Probstfield
JL, O’Leary D, Nasir K. Relationship between common carotid intima-media
thickness and thoracic aortic calcification: the Multi-Ethnic Study of
Atherosclerosis. Atherosclerosis 2010;209:142–6.

4.

Virchow R. Cellular Pathology. As based upon physiological and pathological
histology. Lecture XVI - Atheromatous affection of arteries. 1858. Nutr Rev
1989;47:23–5.

5.

Shroff RC, Shanahan CM. The vascular biology of calcification. Semin Dial
2007;20:103–9.

6.

Speer MY, Yang H-Y, Brabb T, Leaf E, Look A, Lin W-L, Frutkin A, Dichek D,
Giachelli CM. Smooth muscle cells give rise to osteochondrogenic precursors and
chondrocytes in calcifying arteries. Circ Res 2009;104:733–41.

7.

Wu SY, Zhang BH, Pan CS, Jiang HF, Pang YZ, Tang CS, Qi YF. Endothelin-1 is
a potent regulator in vivo in vascular calcification and in vitro in calcification of
vascular smooth muscle cells. Peptides 2003;24:1149–56.

8.

Huang Z, Li J, Jiang Z, Qi Y, Tang C, Du J. Effects of adrenomedullin, C-type
natriuretic peptide, and parathyroid hormone-related peptide on calcification in
cultured rat vascular smooth muscle cells. J Cardiovasc Pharmacol 2003;42:89–
97.

64

9.

Tintut Y, Demer LL. Recent advances in multifactorial regulation of vascular
calcification. Curr Opin Lipidol 2001;12:555-60.

10.

Bataller R, Schwabe RF, Choi YH, Yang L, Paik YH, Lindquist J, Qian T,
Schoonhover R, Hagedorn CH, Lemasters JJ, Brenner DA. NADPH oxidase
signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic
fibrosis. J Clin Invest 2003;112:1383-94

11.

Byon CH, Javed A, Dai Q, Kappes JC, Clemens TL, Darley–Usmar VM,
McDonald JM, Chen Y. Oxidative stress induces vascular calcification through
modulation of the osteogenic transcription factor Runx2 by AKT signaling. J Biol
Chem 2008;283:15319–27.

12.

Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure
and endothelial dysfunction in human essential hypertension by the angiotensin
receptor antagonist losartan. Circulation 2000;101:1653–9.

13.

Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an
angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in
high-risk patients. The Heart Outcomes Prevention Evaluation Study
Investigators. N Engl J Med 2000;342:145–53.

14.

Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M. Selective
angiotensin II receptor receptor antagonism reduces insulin resistance in obese
Zucker rats. Hypertension 2001;38:884–90.

15.

Igarashi M, Hirata A, Yamaguchi H, Tsuchiya H, Ohnuma H, Tominaga M et al.
Candesartan inhibits carotid intimal thickening and ameliorates insulin resistance
in balloon-injured diabetic rats. Hypertension 2001;38:1255–9.

16.

Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving, H-H. Dual blockade of
the renin-angiotensin system versus maximal recommended dose of ACE
inhibition in diabetic nephropathy. Kidney Int 2003;63:1874–80.

65

17.

Hoogwerf BJ. Renin-angiotensin system blockade and cardiovascular and renal
protection. Am J Cardiol 2010;105:30A–5A.

18.

Shobeiri N, Adams MA, Holden RM. Vascular Calcification in Animal Models of
CKD: A Review. Am J Nephrol 2010;31:471–81.

19.

Mizobuchi M, Towler DA, Slatopolsky E. Vascular calcification: the killer of
patients with chronic kidney disease. J Am Soc Nephrol 2009;20:1453–64.

20.

Fishbein GA, Fishbein MC. Arteriosclerosis: rethinking the current classification.
Arch Pathol Lab Med 2009;133:1309–16.

21.

Micheletti RG, Fishbein GA, Currier JS, Fishbein MC. Mönckeberg sclerosis
revisited: a clarification of the histologic definition of Mönckeberg sclerosis. Arch
Pathol Lab Med 2008;132:43–7.

22.

Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee
PJ, McKee MD, Young Jung D, Zhang Z, Kim JK, Mauvis-Jarvis F, Ducy P,
Karsenty G. Endocrine regulation of energy metabolism by the skeleton. Cell
2007;130:456–69.

23.

Ngo DTM, Stafford I, Kelly DJ, Sverdlov AL, Wuttke RD, Weedon H,
Nightingale AK, Rosenkranz AC, Smith MD, Chirkov YY, Kennedy JA, Horowitz
JD. Vitamin D(2) supplementation induces the development of aortic stenosis in
rabbits: interactions with endothelial function and thioredoxin-interacting protein.
Eur J Pharmacol 2008;590:290–6.

24.

Drolet M-C, Arsenault M, Couet J. Experimental aortic valve stenosis in rabbits. J
Am Coll Cardiol 2003;41:1211–7.

25.

Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in
chronic renal disease. J Am Soc Nephrol 1998;9:S16–S23.

66

26.

Lehto S, Niskanen L, Suhonen M, Rönnemaa T, Laakso M. Medial artery
calcification. A neglected harbinger of cardiovascular complications in noninsulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1996;16:978–
83.

27.

Nelson RG, Gohdes DM, Everhart JE, Hartner JA, Zwemer FL, Pettitt DJ,
Knowler WC. Lower-extremity amputations in NIDDM. 12-yr follow-up study in
Pima Indians. Diabetes Care 1988;11:8–16.

28.

Liu Y, Zhou YB, Zhang GG, Cai Y, Duan XH, Teng X, Song JQ, Shi Y, Tang CS,
Yin XH, Qi YF. Cortistatin attenuates vascular calcification in rats. Regul Pept
2010;159:35–43.

29.

El-Abbadi MM, Pai AS, Leaf EM, Yang H-Y, Bartley BA, Quan KK, Ingalls CM,
Wei Liao H, Giachelli CM. Phosphate feeding induces arterial medial
calcification in uremic mice: role of serum phosphorus, fibroblast growth
factor-23, and osteopontin. Kidney Int 2009;75:1297–307.

30.

Panizo S, Cardus A, Encinas M, Parisi E, Valcheva P, López-Ongil S, Coll B,
Fernandez E, Valdivielso J. RANKL Increases Vascular Smooth Muscle Cell
Calcification Through a RANK-BMP4-Dependent Pathway. Circ Res
2009;104:1041–8.

31.

Aikawa E, Aikawa M, Libby P, Figueiredo J-L, Rusanescu G, Iwamoto Y, Fukuda
D, Kohler RH, Shi G-P, Jaffer FA, Weissleder R. Arterial and Aortic Valve
Calcification Abolished by Elastolytic Cathepsin S Deficiency in Chronic Renal
Disease. Circulation 2009;119:1785–94.

32.

Yang X, Fullerton DA, Su X, Ao L, Cleveland JC, Meng X. Pro-osteogenic
phenotype of human aortic valve interstitial cells is associated with higher levels
of Toll-like receptors 2 and 4 and enhanced expression of bone morphogenetic
protein 2. J Am Coll Cardiol 2009;53:491–500.

67

33.

Bas A, Lopez I, Perez J, Rodriguez M, Aguilera-Tejero E. Reversibility of
calcitriol-induced medial artery calcifcation in rats with intact renal function. J
Bone Miner Res 2006;21:484–90.

34.

Zeadin M, Butcher M, Werstuck G, Khan M, Yee CK, Shaughnessy SG. Effect of
leptin on vascular calcification in apolipoprotein E-deficient mice. Arterioscler
Thromb Vasc Biol 2009;29:2069–75.

35.

Nakano-Kurimoto R, Ikeda K, Uraoka M, Nakagawa Y, Yutaka K, Koide M,
Takahashi T, Matoba S, Yamada H, Okigaki M, Matsubara H. Replicative
senescence of vascular smooth muscle cells enhances the calcification through
initiating the osteoblastic transition. Am J Physiol Heart Circ Physiol
2009;297:H1673–84.

36.

You H, Yang H, Zhu Q, Li M, Xue J, Gu Y, Lin S, Ding F. Advanced oxidation
protein products induce vascular calcification by promoting osteoblastic transdifferentiation of smooth muscle cells via oxidative stress and ERK pathway. Ren
Fail 2009;31:313–9.

37.

Tanikawa T, Okada Y, Tanikawa R, Tanaka Y. Advanced glycation end products
induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK.
J Vasc Res 2009;46:572–80.

38.

Li X, Yang H-Y, Giachelli CM. BMP-2 promotes phosphate uptake, phenotypic
modulation, and calcification of human vascular smooth muscle cells.
Atherosclerosis 2008;199:271–7.

39.

Steitz SA, Speer MY, Curinga G, Yang HY, Haynes P, Aebersold R, Schinke T,
Karsenty G, Giachelli CM. Smooth muscle cell phenotypic transition associated
with calcification: upregulation of Cbfa1 and downregulation of smooth muscle
lineage markers. Circ Res 2001;89:1147–54.

68

40.

Bandow K, Nishikawa Y, Ohnishi T, Kakimoto K, Soejima K, Iwabuchi S, Kuroe
K, Matsuguchi T. Low-intensity pulsed ultrasound (LIPUS) induces RANKL,
MCP-1, and MIP-1beta expression in osteoblasts through the angiotensin II type 1
receptor. J Cell Physiol 2007;211:392–8.

41.

Arishiro K, Hoshiga M, Negoro N, Jin D, Takai S, Miyazaki M, Ishihara T,
Hanafusa T. Angiotensin receptor-1 blocker inhibits atherosclerotic changes and
endothelial disruption of the aortic valve in hypercholesterolemic rabbits. J Am
Coll Cardiol 2007;49:1482–9.

42.

Fliser D, Buchholz K, Haller H, EUropean Trial on Olmesartan and Pravastatin in
Inflammation and Atherosclerosis (EUTOPIA) Investigators. Antiinflammatory
effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with
microinflammation. Circulation 2004;110:1103–7.

69

Chapter 3

3

Potential Negative Interaction between Statin Therapy
and Angiotensin Receptor Blockade in Atherosclerotic
Lesion Regression*

While the mortality rate associated with cardiovascular disease is in decline, it remains
the most prevalent cause of death in the United States.1 Atherosclerosis, the underlying
cause of most clinical cardiovascular events, is a chronic disease process involving the
formation of atherosclerotic plaques within the arterial intima. These plaques, which
contain lipid deposits, inflammatory cells, as well as areas of fibrosis and calcification,
are often clinically silent.2 Vulnerable plaques are those that are considered high-risk for
disruption or thrombosis leading to an acute coronary event.3 Pathologically, they are
described as having a large necrotic core, a thin fibrous cap, and inflammatory activity.4,5
While calcification correlates with increased atherosclerotic plaque burden,6,7 the
relationship between calcification and plaque vulnerability is less clear. An intravascular
ultrasound study suggests that an increase in calcification near the base of the lesion is
associated with lower risk of plaque rupture.8 In contrast, Abedin et al.9 argue that as
plaques begin to calcify there is an initial increase in plaque vulnerability because stress
concentrates at the interface between the hard calcium deposits and other, softer
components of the plaque. When these calcium deposits begin to coalesce the risk of
rupture decreases as the interface area decreases.
The renin-angiotensin system directly influences the progression of atherosclerosis and
vascular calcification.10,11 Angiotensin II type 1 receptor blockers (ARBs) have been
shown to cause stabilization,12-14 or even regression,15,16 of atherosclerotic plaques in preclinical and clinical studies. When ARBs are combined with statin therapy, a synergistic
reduction of atherosclerosis burden has been reported.17-19 However, it should be noted

A version of this chapter has been submitted for publication: Armstrong ZB, Boughner DR, Carruthers CP,
Drangova M, Rogers KA. Potential negative interaction between statin therapy and angiotensin receptor
blockade in atherosclerotic lesion regression. Can J Cardiol 2014.
*
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that these studies introduced treatment before the disease was established, and that the
treatment periods were relatively short (4-10 weeks).
The current study uses a model of dietary hypercholesterolemia to further examine the
effects of the ARB olmesartan medoxomil, alone or in combination with atorvastatin
calcium, on the progression of established atherosclerosis. Interestingly, our results
suggest that ARBs promote regression of advanced atherosclerosis when administered
alone, but not in conjunction with statin therapy.

3.1 Methods
3.1.1 Pre-Clinical Model
The animals used in this study have been described previously.20 Briefly, male New
Zealand White rabbits were fed either regular chow (Control, n = 8) or an atherogenic
diet of 0.25% cholesterol to induce atherosclerosis. After 12 months, a subset of Control
(n = 3) and cholesterol-fed (n = 6) rabbits were euthanized for pathological assessment of
disease progression. The remaining diseased rabbits continued on an atherogenic diet of
0.125% cholesterol and received either no treatment (Cholesterol, n = 6), olmesartan
medoxomil (ARB, n = 7), atorvastatin calcium (Statin, n = 7), or a combination of both
drugs (ARB+Statin, n = 7) for an additional 6 months. Olmesartan (1 mg/kg/day) and
atorvastatin (2.5 mg/kg/day) were administered orally. All animals were individually
housed and cared for in accordance with the Canadian Council on Animal Care and all
protocols were approved by the University of Western Ontario Animal Use
Subcommittee.

3.1.2 Micro-Computed Tomography
Following euthanasia, intact aortae were placed in a humidified chamber to prevent
dehydration and scanned with a Locus Ultra micro-computed tomography (micro-CT)
scanner (General Electric Medical Systems, London, ON). Scans were acquired at
80 kVp, 55 mAs and reconstructed with isotropic voxel spacing of 150 µm. Images were
analyzed for the presence of calcium using MicroView analysis software (V2.2, GE
Medical Systems, London, ON). Specifically, the total volume of all voxels containing
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calcified tissue (identified by setting a threshold level) was calculated and expressed as
percent of total vessel volume, as described previously.21

3.1.3 Quantification of Lesion Area
Lesion area was quantified in the thoracic aorta as previously described.22 Aortae were
stained with Oil Red O in propylene glycol for 30 minutes, opened along their ventral
surface and pinned flat for en face analysis. Lesion area was analyzed by a blinded
observer using Adobe Photoshop CS4 Extended (V11, San Jose, CA) and expressed as a
percent of total vessel area.

3.1.4 Histological and Immunohistochemical Analysis
Aortic samples (distal to the first intercostal ostia) were cryopreserved using increasing
concentrations of sucrose (up to 30%) then immediately embedded in Tissue-Tek OCT
(Sakura Finetek, Torrance, CA) compound and frozen in liquid nitrogen-cooled
isopentane. Frozen Sections (10 µm) were taken as cross sections through the aorta.
Serial sections were stained with Oil Red O for extracellular lipid deposition and Alizarin
Red S for calcium deposits (from Sigma-Aldrich, Oakville, ON, Canada).
Immunohistochemical studies were performed using mouse anti-α-smooth muscle actin
(α-SMA; clone 1A4) and mouse anti-rabbit activated macrophage (clone RAM11).
Sections were subjected to single-label immunohistochemistry using an Alkaline
Phosphatase Substrate Kit (Vector Laboratories, Burlingame, CA) and secondary
antibody horse anti-mouse IgG (H+L; Vector Laboratories) Alkaline Phosphataseconjugate according to the manufacturer’s instructions. Negative controls which omitted
the primary antibody were routinely employed. Positive staining areas were calculated by
setting a threshold value in ImageJ (National Institutes of Health, Washington, DC) and
expressed as a percent of total lesion area.

3.1.5 Statistical Analysis
Data is expressed as mean ± SEM and statistically analyzed by one-sample t-test,
unpaired t-test with Welch’s correction, one-way ANOVA with Tukey’s post-hoc test, or
Pearson correlation, as indicated. All analyses were performed using GraphPad Prism
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(V5, GraphPad Software, Inc., La Jolla, CA). Values of p < 0.05 were considered
statistically significant.

3.2 Results
3.2.1 Twelve Months Cholesterol Feeding Induces Advanced
Atherosclerotic Lesions
Atherosclerotic lesion area was significantly increased in Cholesterol animals when
compared to Controls following 12 months of cholesterol feeding (78.15 ± 14.43 %
versus non-detectable for Cholesterol and Control, respectively; n = 6 and 3; p < 0.01;
Figure 3.1A). Total volume of calcium in the thoracic aorta, as examined by micro-CT,
was also significantly increased in Cholesterol animals (1.81 ± 0.50 versus 0.33 ± 0.08 in
Cholesterol and Control, respectively; n = 6 and 3; p < 0.05; Figure 3.1B). Pathological
examination of the thoracic aorta (Figure 3.1C) revealed smooth muscle cell and
macrophage infiltration, predominantly near the surface of the lesion, the area known as
the fibrous cap. Extensive lipid deposition was observed throughout the lesion. Calcium
deposition was also observed, forming as punctate nodules, typically near the base of the
lesion. Taken together, these hallmarks clearly indicate that animals exhibit advance
atherosclerotic lesions after 12 months. This formed the basis upon which progression,
stabilization, or regression during the 6 month treatment period could be assessed.

3.2.2 ARBs Cause Significant Regression of Advanced
Atherosclerotic Lesions when Delivered Alone, but not when
Combined with Statin Therapy
Following the six month treatment period, atherosclerotic lesion area was measured using
en face Oil Red O staining. When compared to Control animals, all treatment groups had
significantly increased lesion area (non-detectable in Control, 95.50 ± 1.94 % in
Cholesterol, 61.61 ± 10.17 % in ARB, 82.50 ± 6.78 % in Statin, and 92.39 ± 3.25 % in
ARB+Statin; n = 5, 5, 7, 7, and 6; P < 0.001 for each group when compared to Control,
significance not shown; Figure 3.2). When compared to untreated Cholesterol animals,
ARB-treated animals had significantly reduced lesion area (P < 0.05). Interestingly,
lesion area was also significantly reduced in ARB-treated animals when compared to
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Figure 3.1: Significant atherosclerosis progression is achieved after 12 months. A:
Atherosclerotic lesion area was significantly increased in Cholesterol animals versus
Control. Each data point represents an individual animal with the mean represented by a
horizontal line. **P < 0.01; by one sample t-test. B: Total volume of aortic calcium, as
measured by micro-computed tomography, was significantly increased in Cholesterol
animals versus Control. Each data point represents an individual animal with the mean
represented by a horizontal line. *P < 0.05; by unpaired t-test with Welch’s correction. C:
Histological and immunohistochemical analyses reveal several markers of
atherosclerosis. Lesions in Cholesterol animals were advanced, with smooth muscle cells
(as indicated by α-smooth muscle actin) forming a fibrous cap, macrophage (indicated by
RAM11) and lipid (indicated by Oil Red O) infiltration, and extensive calcification
(indicated by Alizarin Red S) near the lesion base. Aortae from Control animals showed
no indication of disease. Inset: high-power image of the area indicated by the box.
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Figure 3.2: ARB treatment causes regression of established atherosclerosis.
Atherosclerotic lesion area was significantly increased in Cholesterol, ARB, Statin and
ARB+Statin animals when compared to Control (P < 0.001, not shown). Interestingly,
lesion area in ARB animals was significantly reduced as compared to both Cholesterol
and ARB+Statin animals. Each data point represents an individual animal, with the mean
represented by a horizontal line. *P < 0.05; by one-way ANOVA with Tukey’s post-hoc
test.
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ARB+Statin (P < 0.05), suggesting addition of atorvastatin may interfere with the
beneficial effects of olmesartan. It should also be noted that lesion area in ARB animals
after treatment (Figure 3.2) appears to be lower than before treatment (Figure 3.1A),
consistent with Olmesartan inducing regression of advanced atherosclerotic lesions.

3.2.3 ARBs and Statin Therapy Slows Progression of Atherosclerotic
Plaque Calcification
Given the robust inhibitory effects of olmesartan already observed in aortic medial
calcification,21 the aortae in this study were also examined for total calcium volume using
micro-CT. Cholesterol rabbits had a significantly increased calcium volume when
compared to Control (4.74 ± 1.77 % versus 0.87 ± 0.06 % in Cholesterol and Control,
respectively; n = 6 and 5; P < 0.05; Figure 3.3). This increase was not observed in any of
the treatment groups (1.69 ± 0.25 % in ARB, 1.62 ± 0.41 % in Statin, and 2.47 ± 0.40 %
in ARB+Statin; n = 7, 6, and 6, respectively).

3.2.4 ARBs Do No Affect the Cellular Composition of Atherosclerotic
Plaques
Atherosclerotic lesions were advanced, showing all the hallmarks of classical
atherosclerosis (Figure 3.4). Migration of smooth muscle cells (as indicated by α-SMA)
was robust and typically concentrated on the surface of the lesion, forming a fibrous cap.
Extracellular lipids (indicated by Oil Red O) were distributed throughout the entire
lesion, but were occasionally found concentrated within the core. Macrophage infiltration
(as indicated by RAM11) was also observed throughout the lesion, but was the most
intense on the surface. Calcium was observed as small punctate deposits distributed
throughout the lesion. While lesion area analysis was performed, no significant
differences between groups were observed (Table 3.1). Interestingly, we observed a
significant inverse correlation between macrophage ratio and calcium ratio, such that as
the ratio of macrophages increased, the calcium ratio decreased (P = 0.025; r = -0.43;
Figure 3.5).
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Figure 3.3: Pharmaceutical intervention slows progression of atherosclerotic
calcium. Total volume of aortic calcium was significantly increased in Cholesterol
animals, but not in ARB, Statin, or ARB+Statin animals when compared to Control. Each
data point represents an individual animal, with the mean represented by a horizontal
line. *P < 0.05; by one-way ANOVA with Tukey’s post-hoc test.
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Figure 3.4: Atherosclerotic lesion composition is unaffected by pharmaceutical
intervention. Histological and immunohistochemical analyses reveal hallmark features
of advanced atherosclerotic lesions including fibrous cap formation and smooth muscle
cell (as indicated by α-smooth muscle actin) migration to the surface of the lesion;
macrophage accumulation (indicated by RAM11) both at the surface of the lesion and
within the core; lipid infiltration (indicated by Oil Red O) throughout the lesion, and
extensive calcification (indicated by Alizarin Red S) particularly deep within the core of
the lesion. Morphometric analysis of lesion composition did not reveal any significant
differences between groups (see Table 1). Inset: high-power image of the area indicated
by the box.
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Table 3.1: Lesion composition analysis of thoracic aorta in hypercholesterolemic rabbits.
Group
Control
Cholesterol
Statin
ARB
ARB+Statin

N
5
6
7
7
7

Group
Control
Cholesterol
Statin
ARB
ARB+Statin

N
5
6
7
7
7

Group
Control
Cholesterol
Statin
ARB
ARB+Statin

N
5
6
7
7
7

Group
Control
Cholesterol
Statin
ARB
ARB+Statin

N
5
6
7
7
7

Smooth Muscle Cell (SMC) Area
Total Lesion Area (mm2) SMC Area (mm2)
SMC Ratio (%)
ND
ND
ND
8.58±1.61
3.42±0.59
42.32±4.23
6.23±1.34
3.99±1.07
60.90±3.88
4.30±1.04
2.11±0.48
59.95±12.82
6.31±0.70
3.14±0.58
48.68±4.81
Macrophage (MΦ) Area
Total Lesion Area (mm2) MΦ Area (mm2)
MΦ Ratio (%)
ND
ND
ND
8.30±1.50
1.28±0.51
13.34±3.86
6.27±1.32
2.01±0.91
25.63±6.00
4.81±1.12
0.79±0.33
16.38±4.46
6.21±0.61
1.25±0.25
19.81±3.90
Lipid Area
Total Lesion Area (mm2) Lipid Area (mm2) Lipid Ratio (%)
ND
ND
ND
8.29±1.51
6.04±1.02
76.03±4.34
6.26±1.25
5.01±1.31
75.95±6.78
4.99±1.15
3.77±0.90
74.34±3.30
6.51±0.89
5.07±0.70
75.21±4.34
Calcium Area
Total Lesion Area (mm2) Calcium Area (mm2) Calcium Ratio (%)
ND
ND
ND
8.16±1.63
1.60±0.32
20.99±2.83
5.97±1.32
0.92±0.24
15.33±2.55
4.53±1.08
1.10±0.31
20.64±3.17
6.14±0.76
1.13±0.30
17.28±3.53

Total lesion area was determined as the area between the luminal surface and the internal elastic lamina.
SMC and Macrophage (MΦ) area were determined as positive areas using anti-α-smooth muscle actin
(1A4) and anti-macrophage (RAM11) antibodies, respectively. Lipid and Calcium area were determined as
positive areas using Oil Red O and Alizarin Red S staining, respectively. Data are expressed as mean±SEM.
ND = non-detectable.
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Figure 3.5: Negative correlation between calcium and macrophage ratio in advanced
atherosclerotic lesions. The calcium (as indicated by Alizarin Red S) and macrophage
(as indicated by RAM11) ratio was determined by dividing the total positive staining
area, defined using a threshold value, by the total lesion area, defined as the area between
the luminal surface and the internal elastic lamina. Each data point represents an
individual animal; P = 0.025; r = -0.43.
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3.3 Discussion
The current study examines the effects of an ARB, alone or in combination with statin
therapy, on advanced atherosclerotic lesions. ARB treatment induced atherosclerosis
regression when delivered alone, but not when combined with Statin therapy, a novel
finding that is in contrast with existing pre-clinical studies.18,19,23-26 We also observed a
significant negative correlation between macrophage content and calcification of
atherosclerotic plaques.
Atherosclerotic lesion area was significantly reduced in ARB-treated animals when
compared to untreated Cholesterol animals (Figure 3.2), a result reported consistently by
others.27-31 ARBs induce plaque stabilization,32 decrease expression of adhesion
molecules33 and monocyte adhesion,33,34 reduce production of inflammatory cytokines,35
and inhibit smooth muscle cell migration.36 These pleiotropic effects of ARB therapy may
explain its effectiveness in the treatment of atherosclerosis.
However, we also observed significantly reduced lesion area in ARB-treated animals
compared to those given ARB+Statin therapy (Figure 3.2). Others pre-clinical studies
have reported an additive, 18,19,23 or even synergistic24-26 effect of ARBs and statin therapy
in the prevention of atherosclerosis. These studies have all examined the effects of
therapy in models which employ genetic mutation to induce hypercholesterolemia. Such
models are akin to familial hypercholesterolemia and are not directly translatable to
dietary hypercholesterolemia experienced by the majority of Western society.
Furthermore, only two of these studies induce atherosclerosis before initiating treatment;
19,23

the others have limited ability to analyze treatment effects. Only our model

specifically replicates the chronic, progressive nature of atherosclerosis and properly
examines treatment after disease is established.20,22
While the mechanisms driving smooth muscle cell-mediated calcification in
atherosclerotic plaques have been thoroughly examined,37,38 the relationship between
macrophages and calcification is less clear. In this study we have shown a negative
correlation between macrophages and calcium in atherosclerotic plaques, similar to that
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observed in coronary arteries.39 Conversely, some have suggested that macrophages may
directly promote calcification in atherosclerotic plaques by secreting matrix vesicles that
act as a nidus for hydroxyapatite.40 In addition, Naik et al.41 have shown that up to 20%
of osteochondrogenic cells in atherosclerotic plaques are bone marrow-derived. Clearly,
further studies are required to fully understand the mechanistic interactions between
statins and ARBs in the treatment of atherosclerosis.
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Chapter 4

4

Effects of an Angiotensin II Type 1 Receptor Blocker on
Aortic Valve Sclerosis in a Pre-Clinical Model*

Aortic valve stenosis is a chronic progressive disease involving three factors: lipid
deposition, chronic inflammation, and tissue calcification.1-5 It is the most prevalent
valvular heart disease and the third most common cardiovascular disease behind
hypertension and coronary artery disease.6 It has an incidence of 3–5% in those over the
age of 65 while its precursor, aortic valve sclerosis (AVS), is found in over 25% of
individuals in the same age group.7-9 Patients with AVS have a 50% increased risk of
myocardial infarction and cardiovascular death compared with patients who have a
normal aortic valve.10-12 Currently, there are no clinically-approved pharmaceuticals for
the prevention of AVS; however, when symptoms develop it is managed by prompt valve
replacement, an invasive surgical procedure with high morbidity and mortality.13
AVS shares many risk factors with atherosclerosis including advanced age, male gender,
hypertension, smoking, increased plasma low-density lipoprotein, increased plasma
lipoprotein(a), and diabetes mellitus.1-3,14 This overlap prompted several pre-clinical
studies, the results of which suggested statin therapy as an effective intervention.15,16
However, subsequent clinical trials investigating the effect of statin therapy on AVS
proved unsuccessful.17-20 Indeed, only one pre-clinical study has been consistent with
clinical trials showing lack of effect; Hamilton et al.21 suggested Atorvastatin was an
effective anti-inflammatory agent, but had no demonstrable effect on lipid deposition or
valve calcification.
Blockade of the renin-angiotensin system (RAS) has also been suggested as a potential
therapy for AVS. Two conflicting retrospective studies—one showing no benefit of
angiotensin converting enzyme inhibitors (ACEIs) compared to statins and another
showing a 71% reduction in the progression of valvular calcification—could explain the

A version of this chapter has been accepted for publication: Armstrong ZB, Boughner DR, Carruthers CP,
Drangova M, Rogers KA. Effects of an angiotensin II type 1 receptor blocker on aortic valve sclerosis in a
pre-clinical model. Can J Cardiol 2014.
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lack of prospective clinical trials investigating RAS blockade.22,23 More recent preclinical studies have suggested that olmesartan, an angiotensin receptor blocker (ARB),
can prevent atherosclerotic changes and endothelial disruption,24 while ramipril, an
ACEI, can prevent hemodynamic changes in the valve.25 Indeed, recent results have
prompted two prospective clinical trials investigating the role of ARBs on AVS
(ClinicalTrials.gov Identifiers NCT00699452 & NCT01589380).
Given our recent observation that ARBs can robustly inhibit arterial calcification and the
established anti-inflammatory effects of statin therapy,21,26-28 our objective in the current
study was to investigate potential synergistic effects of these two pharmaceuticals in the
treatment of AVS.

4.1 Methods
4.1.1 Pre-Clinical Model
Male New Zealand White rabbits (1.6 to 2.0 kg, Charles River Laboratories, St-Constant,
QC, Canada) were fed either regular chow (Control, n = 8) or an atherogenic diet
consisting of 0.25% cholesterol to induce aortic valve sclerosis.29,30 After 12 months, a
subset of Control (n = 3) and cholesterol-fed (n = 6) rabbits were euthanized for
pathologic assessment of disease progression. The remaining diseased rabbits continued
on an atherogenic diet and were block randomly assigned to four treatment groups
receiving either no treatment (Cholesterol, n = 6), olmesartan medoxomil (ARB, n = 7),
atorvastatin calcium (Statin, n = 7), or a combination of both drugs (ARB+Statin, n = 7)
for an additional 6 months (Supplementary Figure 4.1). During the treatment period,
dietary cholesterol levels were decreased to 0.125% to reduce the chance of noncardiovascular health issues and prolong the life of the animals. Olmesartan medoxomil
(1 mg/kg/day) and atorvastatin calcium (2.5 mg/kg/day) were administered via oral
gavage, suspended in a solution of 50% molasses in water. Dosages were based on
previous studies using olmesartan medoxomil24 and atorvastatin calcium21 which showed
positive effects in New Zealand White rabbits. At endpoint, animals were euthanized via
intravenous ketamine injection and perfused with Hanks’ balanced salt solution and
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heparin (1 U/mL). All animal protocols were approved by the University of Western
Ontario Animal Use Subcommittee (reference number 2007-023).

4.1.2 Physiological Data
Body weight and blood samples were collected at months 0, 3, 6, 9, 12, 15, and 18 for all
animals. Blood samples were used for the measurement of total cholesterol using a
WAKO Cholesterol E Kit (Wako Chemicals, Richmond, VA), according to the
manufacturer’s instructions.

4.1.3 Magnetic Resonance Imaging
After 12 months of the atherogenic diet, and every three months thereafter, anesthetized
rabbits were imaged using a standardized in vivo pulse sequence on a 3.0 Tesla magnetic
resonance imaging (MRI) scanner (GE Healthcare, Piscataway, NJ), as previously
described.30 Rabbits were imaged in the supine position with a customized two-channel
phased array radio frequency coil positioned over the chest cavity. All imaging was
executed using CINE fast spoiled gradient echo (fSPGR) sequences gated to the cardiac
cycle (peripheral trigger, arrhythmia rejection window = 30, minimum trigger delay, 30
cardiac phases, 2 segments/view). A finger plethysmograph attached to the rabbit’s ear
provided the gating signal. All image analysis was performed off line using ImageJ
(National Institutes of Health, Washington, DC). A blinded observer performed aortic
valve area planimetry measurements at the moment of maximal valve opening using a
double oblique axial image at each time point. In addition, a blinded observer measured
thickness in the middle third of the cusp using the best oblique sagittal image of each
cusp at each time point. We have found interreader variability for measurements such as
these to be moderate with a kappa coefficient of 0.58.30

4.1.4 Histological and Immunohistochemical Analysis
Aortic valve cusps (non-coronary) were cryopreserved using increasing concentrations of
sucrose (up to 30%) then immediately embedded in Tissue-Tek OCT compound (Sakura
Finetek, Torrance, CA) and frozen in liquid nitrogen-cooled isopentane. Frozen Sections
(10 µm) were taken vertically through the cusp and sinus such that sections are taken in

92

the radial direction.1 Serial sections were stained with Oil Red O for lipid deposition and
Alizarin Red S for calcium deposits (both from Sigma-Aldrich, Oakville, ON, Canada).
Immunohistochemical studies were performed using a primary antibody for mouse antirabbit activated macrophage (clone RAM11, Sigma-Aldrich, Oakville, ON, Canada).
Sections were subjected to single-label immunohistochemistry using an Alkaline
Phosphatase Substrate Kit (Vector Laboratories, Burlingame, CA) and secondary
antibody horse anti-mouse IgG (H + L; Vector Laboratories) Alkaline Phosphataseconjugate according to the manufacturer’s instructions. Negative controls which omitted
the primary antibody were routinely used. Positive staining areas were calculated by
setting a threshold value in ImageJ and expressed as a percent of total lesion area.

4.1.5 Statistical Analysis
Data is expressed as mean ± SEM and statistically analyzed by unpaired t-test, KruskalWallis with Dunns post-hoc test, or two-way repeated measures ANOVA with Bonferroni
post-hoc test, as indicated. All analyses were performed using GraphPad Prism (V5,
GraphPad Software, Inc, La Jolla, CA). Values of p < 0.05 were considered statistically
significant.

4.2 Results
4.2.1 Physiological Data
Body weight increased generally with time but did not differ significantly between
treatment groups (Supplementary Table 4.1). Total plasma cholesterol increased
significantly in Cholesterol animals, but not Statin-treated animals, when compared to
Controls (Supplementary Table 4.1).

4.2.2 Dietary Hypercholesterolemia Induced Significant AVS at 12
Months
After 12 months of cholesterol feeding, cusp thickness in Cholesterol rabbits was
significantly increased compared to Control rabbits (0.58 ± 0.03 versus 0.39 ± 0.03 mm
for Cholesterol and Control at 12 months, respectively; n = 18 and 9; P < 0.0001; Figure
4.1A), as assessed by in vivo MRI. While valve orifice area was not significantly affected

93

Figure 4.1: Significant AVS progression is achieved after 12 months. A: Cusp
thickness, measured using in vivo MRI, is significantly increased in Cholesterol animals
versus Control. B: Valve orifice area, a clinical measure of AVS, showed a trend toward
disease, but this did not reach statistical significance (P = 0.128). Histological and
immunohistochemical analyses reveal several markers of AVS. C: Aortic valves from
Cholesterol animals were significantly thickened with marked lipid insudation (Oil Red
O). D: Valves from Cholesterol animals display considerable macrophage (clone
RAM11) infiltration. E: Valves from Cholesterol animals also show minor signs of
calcification (Alizarin Red S). Valves from Control animal showed no indication of
disease. A-B: Each data point represents an individual animal (in A: an individual cusp),
with the median represented by a horizontal line. Statistical significance is indicated by
different superscripts and determined by unpaired t-test. C-E: Representative images
shown; scale bar = 500 μm Inset: High-power image of the area indicated by the box;
scale bar = 100 μm. AVS, aortic valve sclerosis; MRI, magnetic resonance imaging.
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at this time point, there was a trend toward orifice narrowing (0.38 ± 0.03 versus 0.51 ±
0.09 cm2 for Cholesterol and Control, respectively; n = 6 and 3; P = 0.128; Figure 4.1B)
consistent with disease progression. Histological assessment of non-coronary cusps from
Cholesterol animals showed thickening of the fibrosa and other hallmarks of human AVS
including lipid infiltration (Figure 4.1C), inflammation (Figure 4.1D), and calcium
deposition (Figure 4.1E). Lipid infiltration, while not present in cusps from Control
animals, was extensive in Cholesterol animals and distributed throughout the entire cusp
(Figure 4.1C), in contrast with the human disease. Non-coronary cusps from Control
animals contained a few macrophages, typically scattered along the ventricular surface of
the valve. In contrast, cusps from Cholesterol animals contained extensive macrophage
infiltration throughout a thickened fibrosa (Figure 4.1D). Calcification was not found in
cusps from Control animals, and only very minor calcified deposits were found in cusps
from Cholesterol animals at 12 months (Figure 4.1E). Together, these findings confirm
that AVS was well established before pharmaceutical intervention, and provided the basis
on which further progression, stabilization, or regression could be assessed.

4.2.3 In Vivo Monitoring of AVS Progression did not Reveal
Significant Treatment Effects
During 6 months of pharmaceutical intervention, AVS progression was monitored using
MRI. While cusp thickness remained significantly greater in Cholesterol rabbits when
compared to Control (0.465 ± 0.030 versus 0.388 ± 0.023 mm for Cholesterol and
Control at 18 months, respectively; n = 30 and 15; P < 0.05; Figure 4.2A) there was no
significant effect of any treatment group. Similar trends were observed in the data for
valve orifice area, although they didn’t reach statistical significance; valve orifice area in
Cholesterol animals was decreased as compared to Control animals, but no significant
effects of treatment were observed (Figure 4.2B).
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Figure 4.2: In vivo monitoring of AVS does not reveal treatment effect of ARBs,
alone or in combination with statin therapy. A: Aortic valve cusp thickness was
measured at 12, 15, and 18 months using in vivo MRI. While cusp thickness in
Cholesterol animals was significantly increased from Control, there was no significant
effect of ARB, Statin, or ARB+Statin therapy. B: Valve orifice area was significantly
decreased in Cholesterol animals as compared to Control, but there was no significant
effect of ARB, Statin, or ARB+Statin therapy. Data are presented as mean ± SEM. P >
0.05 (not significant) by 2-way repeated measures ANOVA. ARB, angiotensin receptor
blocker; AVS, aortic valve sclerosis; MRI, magnetic resonance imaging.
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4.2.4 Histological Analysis of Non-Coronary Cusps Revealed
Significant Morphological Changes in Response to
Pharmaceutical Intervention
Although treatments were unable to produce macroscopic valvular changes, we did
observe several changes within the valve microenvironment. As expected, cusps from
Control animals showed no signs of lipid infiltration, inflammation, or calcification.
While lipid infiltration into the fibrosa was present in cusps from all animals fed the
atherogenic diet, morphometric analysis indicated that only cusps from Statin animals
had a significantly increased level of lipid when compared to Control (Figure 4.3).
Macrophage infiltration was robust with significantly increased levels of macrophage
staining in cusps from Cholesterol, ARB, and ARB+Statin animals when compared to
Control (Figure 4.4). Interestingly, macrophages in cusps from Cholesterol and ARB
+Statin animals typically concentrated on the surface and in the core of the lesion, while
macrophages in cusps from ARB animals concentrated only in the core and macrophages
in cusps from Statin animals concentrated only on the surface (Figure 4.4). Small,
punctate nodules of calcification were observed in some animals, typically at the base of
the fibrosa (Figure 4.5). Significantly increased levels of calcium were observed in cusps
from ARB and ARB+Statin animals as compared to control. In contrast, cusps from
Cholesterol and Statin animals did not have significantly elevated levels of calcium
deposition.

4.3 Discussion
The current study examined the effects of an ARB, alone or in combination with statin
therapy, on the progression of established aortic valve sclerosis. While clinically-relevant
MRI was unable to detect modulation of disease in vivo, some structural changes were
observed in the valve cusps ex vivo. When compared to Controls, animals treated with
statin therapy alone had significantly increased levels of lipid insudation while animals
from other groups (Cholesterol, ARB, and ARB+Statin) had significantly increased
macrophage infiltration. More importantly, animals treated with ARBs, alone or in
combination with statin therapy, had significantly increased levels of calcification.
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Figure 4.3: Lipid insudation is significantly increased in Statin treated animals, but
not Cholesterol, ARB, or ARB+Statin treated animals. Histological analyses reveal
extensive thickening of the aortic valve with lipid insudation (indicated by Oil Red O) in
all groups except Control. Morphometric analysis revealed a significant increase of lipid
deposition in Statin treated animals as compared to Control. This increase was not
observed in Cholesterol, ARB, or ARB+Statin treated animals. Representative images
shown; scale bar = 500 μm. Inset: High-power image of the area indicated by the box;
scale bar = 100 μm. Each data point represents an individual animal, with the median
represented by a horizontal line. Statistical significance is indicated by different
superscripts and determined by Kruskal-Wallis test with Dunns post-hoc test. ARB,
angiotensin receptor blocker.
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Figure 4.4: Macrophage infiltration is significantly increased in Cholesterol, ARB,
and ARB+Statin treated animals, but not Statin treated animals.
Immunohistochemical analyses reveal macrophage infiltration (indicated by RAM11) in
all groups except Control. Morphometric analysis revealed a significant increase of
macrophage staining in all animals except those treated with Statins. Representative
images shown; scale bar = 500 μm. Inset: High-power image of the area indicated by the
box; scale bar = 100 μm. Each data point represents an individual animal, with the
median represented by a horizontal line. Statistical significance is indicated by different
superscripts and determined by Kruskal-Wallis test with Dunns post-hoc test. ARB,
angiotensin receptor blocker.

100

Figure 4.5: Calcification is significantly increased in ARB and ARB+Statin treated
animals, but not Cholesterol or Statin treated animals. Histological analyses reveal
varying degrees of calcification (indicated by Oil Red O) in all groups except Control.
Morphometric analysis revealed a significant increase of calcification in animals who
received ARBs alone or in combination with Statins. Cholesterol and Statin treated
animals did not have significantly increased amounts of calcification. Representative
images shown; scale bar = 500 μm. Inset: High-power image of the area indicated by the
box; scale bar = 100 μm. Each data point represents an individual animal, with the
median represented by a horizontal line. Statistical significance is indicated by different
superscripts and determined by Kruskal-Wallis test with Dunns post-hoc test. ARB,
angiotensin receptor blocker.
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Despite several successful pre-clinical studies,15,16 clinical trials have consistently shown
no beneficial effect of statin therapy in the management of AVS.17-19,31 To date, our longterm dietary cholesterol model30 is the only pre-clinical model which suggests statin
therapy has limited potential in the treatment of AVS and is the only pre-clinical model
consistent with prospective human trials.21 As a result, after the failure of statin therapy in
the treatment of AVS,17-19,21,31 we set out to examine the effects of ARBs, a strategy that
has been suggested by us and others.32,33 Initial results using ACEIs were conflicting;
however, two clinical trials studying the effects of ARBs on the progression of AVS are
currently recruiting, suggesting continued interest in using ARBs to treat AVS
(ClinicalTrials.gov Identifiers NCT00699452 & NCT01589380).
To our knowledge, the current study is the first to use a pre-clinical model to examine the
effects of combined ARB and statin therapy in the treatment of AVS. Despite using
clinically-relevant measures (Figure 4.2) and ex vivo histological analysis (Figures
4.3-4.5), we did not observe any clinically significant treatment effect of ARBs, alone or
in combination with statin therapy. Our findings contrast with those of previous work
which suggested RAS blockade may prevent atherosclerotic changes within the aortic
valve.24,25 It is important to note, however, that the models used in those studies were
short-term and therefore could not replicate the slowly progressive nature of clinical AVS.
Furthermore, neither study was able to show valvular calcification, a hallmark of
advanced AVS.24,25 The valves in our study displayed varying degrees of calcification
even before the introduction of therapy (Figure 4.1E), suggesting we initiated therapy in
the late-stage of the disease process and thereby replicated the clinical practice. Given
prevailing opinion that pharmaceutical intervention should be administered early,34 it
remains possible that our intervention was initiated too late to affect the course of the
disease.
While the current study was unable to demonstrate significant structural changes,
significant changes in the valvular microenvironment were observed. Consistent with
previous work done by our lab,21 we observed an inverse relationship between
macrophage infiltration and lipids. In Statin animals we observed significantly increased
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lipid deposition when compared to Control animals. Conversely, the Statin group was the
only one without significantly increased levels of macrophages. This suggests, as we’ve
argued previously, that the primary role of macrophages in AVS is lipid extraction.21
Additionally, the localization of macrophages within cusps appeared to change depending
on the treatment. Macrophages in the cusps of ARB-treated animals were found
predominantly in the core of the valvular lesion, while macrophages in the cusps of
Statin-treated animals concentrated on the fibrosa surface. Given recent reports
suggesting macrophages may increase vascular calcification in a paracrine manner,35 it
may be important to understand and manage the distribution of macrophages within the
valvular microenvironment if we are to modulate valve calcification.
The current study suggests that angiotensin II type 1 receptor blockers, alone or in
combination with statin therapy, may not be a suitable treatment for AVS. While we
remain cautiously optimistic about ongoing clinical trials, it has become clear that further
research into the unique mechanisms underlying aortic valve disease is required to
generate suitable pharmaceutical management.
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Chapter 5

5

General Discussion

5.1 Summary of Results and Conclusions
We have utilized two pre-clinical models to examine the effects of an angiotensin II
(AngII) type 1 receptor blocker (ARB), olmesartan medoxomil, on the three main classes
of cardiovascular calcification: arterial calcification, intimal calcification, and calcific
aortic valve disease. Where appropriate or suggested by evidence, statins were examined
in conjunction and in combination with ARBs. In vivo and ex vivo techniques were used
to assess overall disease burden and the extent of calcification including magnetic
resonance imaging, micro-computed tomography, histology, and immunohistochemistry.
Interestingly, the ARB olmesartan medoxomil was able to robustly inhibit arterial
calcification, but showed little effect in halting intimal or valvular calcification (Figure
5.1). Even when combined with statins, the ARB was unable to inhibit intimal or valvular
calcification and, at least in the aortic valve, may have promoted its progression. Taken
together, our results suggest that distinct molecular mechanisms may give rise to arterial,
intimal, and valvular calcification.

5.1.1 Arterial Calcification
We have provided the first evidence that suggests ARBs as a novel therapy for arterial
calcification. Using ex vivo micro-computed tomography and histology, we have shown
that an ARB can robustly inhibit arterial calcification well after the disease process is
underway. We also provided clues to the underlying molecular mechanisms involving
osteogenic differentiation of vascular smooth muscle cells (VSMCs) including early
down-regulation of the typical VSMC marker α-smooth muscle actin and upregulation of
the osteogenic differentiation marker bone morphogenetic protein-2.

5.1.2 Intimal Calcification
We also examined the effects of an ARB and a statin, alone or in combination, on the
progression of atherosclerosis and intimal calcification. ARBs may have induced
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Figure 5.1: An angiotensin II type 1 receptor blocker effectively inhibits arterial
calcification, but not intimal calcification or calcific aortic valve disease. The
angiotensin II type 1 receptor blocker (ARB) olmesartan robustly inhibited arterial
calcification within the medial layer of the artery, but may have only slowed progression
of intimal calcification. In the aortic valve, the ARB may have promoted the progression
of calcification.
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significant regression of atherosclerotic lesion area when delivered as monotherapy but
not when combined with statins. In addition, the progression of intimal calcification may
have been inhibited by both ARBs and statins, although the lack of longitudinal in vivo
monitoring means this remains speculative. The effects of ARBs on atherosclerotic lesion
composition were unclear.

5.1.3 Calcific Aortic Valve Disease
Finally, we examined the effects of an ARB, alone or in combination with a statin, on the
progression of established aortic valve sclerosis (AVS). While in vivo magnetic resonance
imaging was unable to detect any demonstrable treatment effects, ex vivo histological
examination revealed significant structural changes within valve cusps. Interestingly,
animals treated with ARBs, whether alone or combined with statins, had significantly
increased levels of calcification in their aortic valve cusps when compared to those from
control animals (Figure 4.5).

5.1.4 Three Distinct Mechanisms
While arterial calcification was generally thought to be irreversible, inhibiting its
progression remains the goal of several groups.1-6 We were the first to describe the robust
inhibition of arterial calcification by an ARB. However, the ARB only inhibited
calcification of the tunica media. Indeed, a few micro-calcifications were observed within
atherosclerotic plaques of both ARB-treated and untreated animals (Figure 2.2),
providing evidence suggesting that ARBs may specifically inhibit arterial calcification of
the media, and that the mechanisms giving rise to arterial calcification and intimal
calcification are distinct. The failure of ARBs to inhibit progression of intimal
calcification (Table 3.1) also supports this theory.
Recently, Speer et al.1 performed an elegant fate mapping study to understand the cell
types that give rise to calcification of the media. They showed that transdifferentiation of
resident VSMCs to an osteochondrogenic state was the crucial mediator of arterial
calcification. More recently, Naik et al.7 have performed a similar fate mapping study
examining calcification within atherosclerotic plaques. They found 75–88% of
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osteochondrogenic cells observed in atherosclerotic plaques were derived from VSMCs,
but they also noted up to 20% were bone-marrow derived. This could provide a clue as to
the underlying mechanism whereby ARBs inhibit arterial calcification. If ARBs act
directly on VSMCs to exert their anti-calcification effects, it is possible that the bonemarrow derived cells are unaffected and able to continue the calcification process.
However, macrophages in the atherosclerotic plaque have been shown to express the
AngII type 1 receptor (AT1R) by us (Figure 2.3) and others,8 and AngII acting through
the AT1R in macrophages has been shown to promote atherosclerosis.9 Therefore, it
stands to reason that ARBs would also be effective at blocking the pro-calcific effects of
AngII in bone-marrow derived cells. However, it remains possible that the mechanism
driving osteochondrogenesis in bone-marrow derived cells is AngII-independent. It is
also possible that bone-marrow derived cells secrete additional pro-calcific mediators that
reactivate the osteochondrogenic transition in VSMCs in an AngII-independent manner.
Clearly, more work needs to be done to understand the mechanisms at play in both
arterial and intimal calcification.
The same is true for calcific aortic valve disease. Despite the effectiveness of ARBs at
reducing advanced atherosclerotic lesions (Figure 3.2), they have little or no effect on
AVS (Figure 4.2). Statins face a similar dilemma when treating atherosclerosis and AVS:
effective in the former,10-15 but not the latter.16 Although much has been made of the
strong resemblance of AVS to atherosclerosis, it must be remembered that these processes
are separate and involve structurally distinct tissues. Arteries involved in atherosclerosis
are three layered structures with atherosclerotic lesions developing in the thin cellular
intima and the final clinical result being a lipid filled plaque and plaque instability. The
aortic valve also has a three-layered structure, but the layer primarily involved in the
disease process, the fibrosa, is a highly-organized, collagenous structure and the final
outcome is a thickened, calcified valve that fails to perform its required function.17
Furthermore, the resident cells are distinct: VSMCs play a role in atherosclerosis while
valvular interstitial cells (VICs) are present in the valve. VICs, like VSMCs, possess
osteochondrogenic potential and contribute to calcification.18 Osteogenic differentiation
of VICs is regulated by many of the same inflammatory factors as VSMCs including C-
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type natriuretic peptide,19 reactive oxygen species,20,21 and transforming growth factorβ1.22 However, VICs are also regulated by additional factors such as matrix stiffness23
and mechanical stress.24 Clearly, a multitude of factors are involved in the progression of
calcific aortic valve disease and it remains unclear whether the mechanisms underlying
calcification of VICs is distinct from that observed in VSMCs. Indeed, the National Heart
and Lung and Blood Institute Aortic Stenosis Working Group in 2011 recommended that
further research be done to understand the basic biology of calcific aortic valve disease.25

5.2 Clinical Implications
The most important clinical implication of this work is the suggestion that ARBs may
robustly inhibit arterial calcification. To date, there are no methods for pharmaceutical
intervention of arterial calcification, a disease that may affect 30–50% of asymptomatic
patients26 and is associated with increased morbidity and mortality,27-30 increased risk of
amputation,31 and may lead to necrosis or ulceration of the skin.32,33 Despite an
incomplete understanding of the underlying mechanisms leading to inhibition, the fact
that ARBs are already approved for the treatment of hypertension means that they could
rapidly move through clinical trials to assess arterial calcification. The evidence put
forward by us and others34-37 should provide the impetus to explore the role of ARBs in a
clinical setting.
A potential negative interaction between ARBs and statins is another important clinical
implication of this work, since hypertension and hypercholesterolemia frequently coexist
in patients.38,39 According to the United States National Health and Nutrition Examination
Surveys from 1988-2010, more than 60% of hypertensive patients were also
hypercholesterolemic.40 Over that same period, dual intervention for hypertension and
low density lipoprotein (LDL)-cholesterol rose from 5.0 to 30.7%. It is unclear what
proportion of prescribed antihypertensives were ARBs in this survey; however, another
study has shown the proportion of patients taking ARBs to be 17–22.6%.41 Clearly, a
significant number of patients are currently prescribed ARBs and statins which may be
preventing some of the anti-atherosclerotic effects each drug confers when delivered as
monotherapy.
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The renin-angiotensin system (RAS) has been the primary focus of several groups
searching for pharmaceutical interventions for the clinical management of AVS.42-45
Indeed, at the time of writing, two clinical trials were recruiting patients to examine the
effects of ARBs. ROCK-AS (the potential of candesartan to retard the progression of
aortic stenosis), by Kupari et al., is examining the role of candesartan on inflammation,
calcification, lipid deposition, and fibrosis of the aortic valve (ClinicalTrials.gov
Identifier: NCT00699452). ALFA (a randomized trial of Angiotensin receptor bLocker,
Fimasartan, in Aortic stenosis), by Kim et al., is examining the effects of fimasartan on
change in exercise capacity and other symptoms of AVS (ClinicalTrials.gov Identifier:
NCT01589380). ALFA is also examining classical hemodynamic measures of AVS
including aortic jet velocity and mean pressure gradient across the valve. While we
remain cautiously optimistic about these ongoing clinical trials, our pre-clinical model
suggests that ARBs may not be suitable for the prevention of AVS. They also provide
impetus for a deeper examination of the molecular mechanisms underlying valvular
calcification within the complex atherosclerotic milieu that characterizes AVS.

5.3 Limitations
The conclusions drawn in this work are based on pre-clinical models, which are useful
tools for understanding mechanisms of disease processes that are difficult or impossible
to study in humans. However, they are still based on animals, and may not be directly
translatable to clinical practice. It should also be noted, with regard to Chapter 2, that the
role of Vitamin D2 in the progression of arterial calcification in humans remains
controversial.46,47
Often, pre-clinical treatment studies initiate the potential therapy alongside the diseaseinitiating state.48,49 If this experimental design were theoretically applied to a clinical
setting, it would involve treating children from birth. Others use an atherogenic diet that
far exceeds any physiological norm (1 or 2% cholesterol), creating disease states that are
morphologically and histologically dissimilar to the human condition and akin to familial
hypercholesterolemia or lipid storage disease (>1000mg/dL plasma cholesterol).48,50-52
Neither experimental paradigm is ideal since cardiovascular disease is developed slowly,
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over the course of a lifetime and treatment is not initiated until the disease process is well
established. Our work was done with painstaking commitment to replicate the clinical
setting. Animals were administered a low-level cholesterol diet over a long time period
and treatment was initiated well after the disease was underway. As an example, rabbits
in our studies had approximately 75% of their aortic surface covered by atherosclerotic
lesion and a 50% increase in the thickness of their aortic valve before treatment was
initiated. In contrast, treatment studies by other groups have described atherosclerotic
lesion areas in the range of 12% to 18% at endpoint,53,54 and studies that have identified
regression of AVS have observed a reduction in valve thickness of only 30%.55,56 The
experimental design is absolutely crucial when performing pre-clinical studies, and ours
has been shown to remain consistent with clinical trials.16,57
The effect of statins in our model - or, indeed, in any animal model - also deserves
attention. Statins, or 3-hydroxy-3-methylglutaryl Co-enzyme A (HMG-CoA) reductase
inhibitors, lower cholesterol levels by inhibiting HMG-CoA reductase, the rate limiting
enzyme in endogenous cholesterol production. Many animal models, including those in
rabbits and rats, are based on exogenous cholesterol; they induce high cholesterol through
an enriched diet. It is understandable, therefore, to question the effectiveness of a drug
that inhibits endogenous cholesterol production when experimental models have very
little endogenous cholesterol and induce disease via exogenous cholesterol. However,
statins are well known to have anti-inflammatory pleiotropic effects that are unrelated to
cholesterol lowering.58-61 Since our model is primarily exogenous cholesterol, we are able
to study the pleiotropic effects of statins in isolation from their cholesterol lowering
effects.
One of the chief methodological limitations in this work is the lack of blood pressure
data. Obviously, when examining the effects of blood pressure lowering medication it
would be prudent to assess the effects on blood pressure. However, measuring blood
pressure in rabbits is notoriously difficult, in contrast to the simplicity of mice and man.
Previous studies using an identical dose of olmesartan medoxomil in rabbits measured
blood pressure invasively for 30 minutes using the SURFLO Flash catheter at the study
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endpoint.62 While it is not noted in their manuscript, rabbits surely would have been
anesthetized, however slightly, which undermines the reliability of pressure
measurements. That being said, they observed no change in blood pressure after 4 weeks
of treatment. We suspect that the effects of ARBs we observed are independent of its
effect on blood pressure, but can’t be certain without quantitative data.
Another methodological limitation is the lack of hemodynamic data in relation to the
aortic valve. Clinical severity of aortic valve disease is assessed using an array of
hemodynamic and natural history data including aortic jet velocity, mean pressure
gradient, and valve orifice area.63 In rabbits, standard Doppler echocardiography is used
to assess the progression of aortic valve disease.64-66 Ultrasonic backscatter has been used
with success in humans,67,68 rats,69 and rabbits70 to measure the echogenicity of the aortic
valve as an indicator of disease severity. These methods have also been used to assess the
effects of an Apo-A1 mimetic peptide,55,56 the angiotensin converting enzyme inhibitor
(ACEI) rampril,43 as treatments of aortic valve disease. While these methods would have
been a valuable addition to our work, we did not have the required facilities or technical
expertise to perform these measurements. However, we did use MRI to monitor valve
thickness and valve orifice area in our model. This showed limited success in detecting
the presence of aortic valve disease, but was not sufficiently sensitive to detect changes as
a result of treatment.

5.4 Conclusions
This work provides evidence that ARBs robustly inhibit arterial calcification, a disease
commonly associated with advanced age, chronic kidney disease (CKD), and diabetes
mellitus, and is the first to suggest ARBs as a novel treatment option for those at risk for
cardiovascular calcification. It also suggests that ARBs may not be beneficial for those at
risk for intimal or valvular calcification which are more commonly associated with an
atherosclerotic milieu. These disparate results suggest that the classes of cardiovascular
calcification are distinct from one another and provides impetus to further examine the
underlying molecular mechanisms at play in these debilitating disease processes.
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5.5 Future Directions
Recognizing the fact that there is currently no pharmaceutical therapy available to
patients and the robust inhibitory effect of ARBs we observed in our pre-clinical model,
arterial calcification should be the primary focus of future research. To date, there have
been no prospective, clinical trials specifically examining the role of RAS blockade on
arterial calcification. Such a trial would be desirable, particularly if it focused on patients
who are prone to rapid development of arterial calcification. To test the applicability of
my results, we believe a prospective, randomized trial examining the effects of an ARB
on arterial calcification in patients with Stage 3 CKD (glomerular filtration rate of 30-59
mL/min) would be valuable. Exclusion criteria should include subjects on dialysis,
subjects with a recent or scheduled kidney transplant, subjects who are pregnant or
planning to become pregnant in the next 18 months, and subjects who are currently
prescribed ARBs, ACEIs, or direct renin inhibitors. Patients would be randomly assigned
to receive either placebo or olmesartan medoxomil (20 mg/day). Primary outcome
measures should be the change from baseline in arterial calcification after 18 months,
determined using spiral computed tomography. Secondary outcomes could include
calcification of the superficial femoral arteries and/or arterial stiffness as measured by
pulse wave velocity. A clinical trial by Toussaint et al.71 described the extent of
progression of arterial calcification in CKD patients over a period of 18 months and
found the difference from baseline for the entire cohort was +119.6 Hounsfield Units
(HU). Using that number, as well as the typical standard deviation they observed (± 250
HU), a sample size of 138 patients (69 each receiving placebo and olmesartan) would be
required for 80% power.
Many questions remain about the underlying molecular mechanisms leading to
cardiovascular calcification. Experimentally, arterial calcification is the most
straightforward of the three diseases to study, at least from a molecular standpoint, and
thus should represent the immediate focus of future in vitro studies. At its most basic
level, arterial calcification is the calcification of VSMCs in an environment made up
primarily of VSMCs, with some paracrine factors from adventitial myofibroblasts and
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endothelial cells in the intima. In contrast, atherosclerosis and AVS are each characterized
by a complex atherosclerotic milieu. In addition to resident VSMCs or VICs, a typical
lesion may also contain macrophage foam cells, lymphocytes, and/or mast cells; even
endothelial cells have been shown to influence the process in a paracrine manner.72 This
complexity makes studying atherosclerosis and AVS in vitro extremely difficult.
Therefore, a deeper understanding of the mechanisms driving VSMC transdifferentiation
in arterial calcification could help focus attention on the most important aspects of that
atherosclerotic milieu with regard to intimal or valvular calcification.
Ultimately, much more work needs to be done to understand the basic biology of
cardiovascular calcification and its clinical implications. Future research should focus on
areas with the potential for greatest impact, namely, clinical studies examining the effects
of ARBs on arterial calcification and further investigating the biology underlying all three
disease processes.
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Appendices
Supplementary Results
Arterial calcification is detected after eight weeks on the atherogenic
diet
To assess the state of disease progression before pharmaceutical intervention, a subset of
Control and Cholesterol animals were sacrificed after eight weeks on the atherogenic
diet. Focal areas of calcification were detected by micro-CT in one Cholesterol animal
but did not reach a statistically significant volume (non-detectable versus 0.58 ± 0.58 %
calcified tissue in Control and Cholesterol, respectively; n = 3/group; P = ns;
Supplementary Figure 2.1A). Subsequent histological examination revealed calcification
in a second Cholesterol animal; these regions - reflecting calcification at the initial stages
- were too small (~30 µm) to have been identified with the micro-CT protocol we
employed. In all cases, calcification was localized to the IEL and extended outward to the
media (Supplementary Figure 2.1B), typical of arterial calcification and Mönckeberg
sclerosis.
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Supplementary Figure 2.1: Arterial calcification, localized to the IEL and medial
layer, is present after 8 weeks on the atherogenic diet. (A) Maximum intensity
projections, derived from micro-computed tomography (CT) scans, and corresponding
quantitation (n = 3/group) show calcification is widespread in one Cholesterol animal, but
nonexistent in Control animals. Scale bar = 4 mm. One sample t-test: P = ns. (B)
Histological examination of calcium (Alizarin Red S, top) and calcium salts (Von Kossa,
bottom) reveals they are localized primarily to the internal elastic lamina (IEL) and
medial layer, typical of arterial calcification. Scale bar = 500 µm. ND = none detected.
Arrows indicate calcification.
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Supplementary Figure 2.2: Treatment with the angiotensin II type 1 receptor
blocker has no effect on systemic disease parameters. (A) Total plasma cholesterol
was significantly increased in Cholesterol animals as compared to Control, but was
unaffected by ARB treatment. One-way repeated measures ANOVA with Tukey’s posthoc test: P < 0.001. (B) Levels of inorganic phosphate were affected neither by the
atherogenic diet nor ARB therapy. Kruskal-Wallis test with Dunns post-hoc test: P = ns.
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Supplementary Figure 2.3: Characterization of calcified regions indicates an
osteoblast-like phenotype. Immunohistochemical characterization of calcified regions
(arrows) and adjacent sections reveals colocalized expression of the osteogenic growth
factor bone morphogenetic protein 2 (BMP2), the bone protein and osteoblast-specific
marker osteocalcin (OCN), and dramatic upregulation of the angiotensin II type 1
receptor (AT1R). This data suggests an osteoblast-like phenotype within the calcified
areas. Scale bar = 500 µm.
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Supplementary Figure 2.4: Calcified regions of the media are not associated with
smooth muscle cells or macrophages. Examination of α-smooth muscle actin (α-SMA),
a marker of smooth muscle cells, reveals dramatic downregulation in calcified regions
(arrows). Interestingly, α-SMA is also downregulated in some non-calcified areas.
Furthermore, macrophages are localized specifically to atherosclerotic plaques, and are
not associated with areas of calcification. Scale bar = 500 µm.
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Supplementary Figure 4.1: Experimental design. A pre-clinical model was used to
investigate the effects of an angiotensin II type 1 receptor blocker (ARB), alone or in
combination with a statin, on intimal calcification and atherosclerosis. Male New Zealand
White rabbits were fed either regular chow (Control) or an atherogenic diet to induce
atherosclerosis (Cholesterol). After 12 months, a subset of Control and Cholesterol
rabbits were euthanized for pathological assessment of disease progression. The
remaining rabbits continued on an atherogenic diet and received either no
treatment (Cholesterol), olmesartan medoxomil (ARB), atorvastatin calcium (Statin), or a
combination of both drugs (ARB+Statin) for an additional 6 months.
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Supplementary Table 4.1: Physiological data
Control

Cholesterol

ARB

Statin

ARB+Statin

Body weight (kg)
Baseline

1.91 ± 0.02

Month 3

2.84 ± 0.03

3.04 ± 0.04*

Month 6

3.25 ± 0.07

3.37 ± 0.04

Month 9

3.31 ± 0.08

3.51 ± 0.04*

Month 12

3.48 ± 0.09

3.51 ± 0.04

Month 15

3.64 ± 0.13

3.59 ± 0.04

3.56 ± 0.08

3.73 ± 0.09

3.72 ± 0.08

Month 18

3.65 ± 0.14

3.57 ± 0.06

3.66 ± 0.08

3.83 ± 0.09

3.73 ± 0.05

Total plasma cholesterol (mg/dL)
Baseline

115.2 ± 4.0

Month 3

76.1 ± 11.5

602.7 ± 45.9****

Month 6

30.4 ± 8.4

731.3 ± 65.1****

Month 9

48.1 ± 6.0

719.2 ± 64.1****

Month 12

23.1 ± 3.6

614.9 ± 58.4***

Month 15

26.2 ± 3.7

502.7 ± 94.1*

499.7 ± 118.8*

410.1 ± 59.5

514.3 ± 78.5*

Month 18

20.0 ± 2.9

400.2 ± 107.2

498.2 ± 122.2*

328.6 ± 46.3

517.0 ± 89.6**

Data are mean±SEM
*Indicates significantly different from Control (P<0.05).
**Indicates significantly different from Control (P<0.01).
***Indicates significantly different from Control (P<0.001).
****Indicates significantly different from Control (P<0.0001).
All analyses used a Mann-Whitney test or Kruskal-Wallis test with Dunn’s post-hoc test, as
appropriate.
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